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ABSTRACT OF DISSERTATION 
CHRONIC WASTING DISEASE: A MODEL FOR PRION TRANSMISSION VIA 
SALIVA AND URINE 
 Chronic wasting disease (CWD) of cervids is a prion disease distinguished by its 
high level of transmissibility, wherein bodily fluids and excretions are thought to play an 
important role.  Typical of all prion diseases, CWD is characterized by the forced 
conversion of the normal prion protein (PrPC) into a misfolded isoform (PrPCWD), which 
has been shown to accumulate primarily in tissues of the lymphoid and nervous systems, 
though has also been found in other peripheral tissues including elements of the 
cardiovascular, musculoskeletal, and urogenital systems.  Despite strong evidence that 
natural infection is acquired from the environment, as well as saliva and blood, a more 
thorough evaluation of excreta, including saliva, urine, and feces, is essential for a 
comprehensive foundation for (1) understanding how environmental CWD-
contamination occurs, (2) developing in vitro assays for the antemortem identification of 
CWD-infected cervids, and (3) demonstrating the pathogenesis of the disease in the 
natural host.  
 In this dissertation, two approaches are used to identify infectious CWD prions 
and PrPCWD in the bodily fluids and tissues of CWD-exposed white-tailed deer: a novel 
bioassay system using a transgenic mouse line expressing the cervid PrP protein 
(Tg[CerPrP] mice), and a recently developed prion amplification assay known as serial 
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protein misfolding cyclic amplification (sPMCA).  In conjunction with 
immunohistochemistry and western blotting, these two assays were used to definitively 
identify CWD prions in saliva and urine, in addition to elements of the lymphoreticular 
system, central and peripheral nervous systems, and urogenital and oropharyngeal tissues.      
 In initial experiments, concentrated urine and saliva samples from terminal 
CWD+ white-tailed deer, suspected of harboring infectious CWD prions, was assessed by 
Tg[CerPrP] bioassay and sPMCA.  Authentic prion infectivity was detected in urine and 
saliva using both detection systems in the case of urine, though only mouse bioassay 
successfully demonstrated CWD prions in saliva.  The concentration of abnormal prion 
protein in bodily fluids was very low, as indicated by: undetectable PrPCWD levels by 
traditional assays (western blot, ELISA) and prolonged incubation periods and 
incomplete TSE attack rates in inoculated Tg[CerPrP] mice.  These findings helped to 
extend the understanding of CWD prion shedding and transmission and portend the 
detection of infectious prions in body fluids in other prion infections.   
  Based on the identification of CWD prions in saliva (“prionsialia”) and urine 
(“prionuria”), I next sought to determine whether deer previously exposed orally to urine 
and feces from CWD+ sources, while conventional test-negative, may actually be 
harboring very low level CWD infection not evident in the 19 month observation period 
in initial cervid bioassay studies.  A selection of tissues, including those of the 
lymphoreticular and both central and peripheral nervous systems were fully examined, 
initially using Tg[CerPrP] bioassay to demonstrate true infectivity, and secondarily with 
sPMCA.  Positive controls consisted of issues from CWD+ deer exposed orally to saliva; 
negative control tissue sets were collected from deer exposed orally and intracranially to 
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CWD-negative brain.  PrPCWD was detected in the tissues of orally exposed deer by both 
sPMCA and Tg[CerPrP] mouse bioassay; each assay revealed very low levels of CWD 
prions previously undetectable by western blot, ELISA, or IHC.  Serial PMCA analysis 
of individual tissues identified that obex alone was positive in urine/feces exposed deer. 
PrPCWD was amplified from both LRS and neural tissues of positive control deer but not 
from the same tissues of negative control deer.  Detection of subclinical infection in deer 
orally exposed to urine and feces (1) suggests that a prolonged subclinical state can exist 
such that observation periods in excess of two years may be needed to detect CWD 
infection, and (2) illustrates the sensitive and specific application of sPMCA in the 
diagnosis of low-level prion infection.   
Despite the confirmation of infectious prions in urine and saliva, along with 
conventional test-negative deer exposed to urine and feces, the manner in which 
infectivity is transferred to these excreta is unknown.  To address this, I went on to apply 
sPMCA to tissues associated with production and excretion of urine and saliva in an 
effort to seek proximal sources of prion shedding.  I blindly analyzed oropharyngeal and 
urogenital tissues, reproducibly demonstrating PrPCWD in each tissue examined in 3 
rounds of sPMCA; whereas blood samples from the same animals and concurrent 
negative controls remained negative.  Tissue distribution was affected by route of 
inoculation and CNS burden.  The identification of PrPCWD in bodily fluids and 
conventional-test negative tissues – in the absence of detection by conventional methods 
– may indicate the presence of protease-sensitive infectious prions in excretory tissues 
not revealed by assays employing PK digestion or other means to remove PrPC reactivity. 
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The continued evaluation of bodily fluids and peripheral tissues via sPMCA may 
therefore allow additional insights into prion transmission, trafficking, and pathogenesis. 
Nicholas James Haley 
Department of Microbiology, Immunology and Pathology 
Colorado State University 
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The prion diseases:  
 Prion diseases – transmissible spongiform encephalopathies or TSEs - are 
infectious, progressive and uniformly fatal neurodegenerative diseases of humans and 
animals.  The designation “prion disease” is based on the association of these diseases 
with aggregates of a conformationally altered and post-translationally modified isoform 
of the normal cellular prion protein (PrPC) (Williams 2005).  In the course of disease, the 
normally α-helical rich prion protein, which is a detergent-soluble, protease-sensitive, 
glycophosphatidylinositol (GPI) anchored membrane-bound sialoglycoprotein, is 
converted into a detergent-insoluble, protease-resistant, β-sheet rich isoform (Weissmann 
and Flechsig 2003).  Low molecular weight aggregates of this isoform, typically defined 
by a 27-30kDa protease-resistant “core” protein demonstrable by western blotting, have 
been shown to correlate strongly with both infection and disease (Bolton, Rudelli et al. 
1991; Race, Jenny et al. 1998; Tzaban 2002; Silveira, Raymond et al. 2005). The studies 
described in this dissertation are framed in the context of the most widely accepted 
paradigm for the etiology of TSE’s: the protein-only hypothesis, in which it is postulated 
that TSE’s occur as a result of infection with the relatively protease-resistant isoform, 
PrPres, that propagates by translating its altered biophysical characteristics to native PrPC 
(Griffith 1967; Soto and Castilla 2004).  The misfolded isoform has been designated 
variously, including PrPSc (scrapie-associated abnormal prion protein), PrPres (protease-
resistant abnormal prion protein), and PrPd (disease-associated prion protein).  In this 
dissertation, the term “PrPres” will be used to describe term infectious prion proteins in a 
general sense, while the expression conventionally applied to CWD prions, “PrPCWD,” 
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will be used to denote the infectious prion protein associated with chronic wasting 
disease (CWD).  Apart from iatrogenic transmission of human prions via tissue 
transplantation, dentistry, and blood transfusion, surprisingly little is known about the 
natural routes of prion transmission, though accumulating research points to a strong role 
for excreta, including saliva, urine, and feces (Hadlow, Eklund et al. 1974; Williams and 
Young 1992; Miller and Williams 2004; Seeger, Heikenwalder et al. 2005; Kariv-Inbal, 
Ben-Hur et al. 2006; Mathiason, Powers et al. 2006; Murayama, Yoshioka et al. 2007; 
Safar, Lessard et al. 2008).  This latter aspect of prion pathogenesis, transmission as 
modeled by the naturally occurring prion disease of cervids, CWD, is the subject of 
studies described in this dissertation. 
 
Molecular biology of the prion protein: 
 The cellular prion protein, PrPC (Figure I-1), is an approximately 209 amino acid 
protein serendipitously discovered by Prusiner and colleagues in 1982 while searching 
for molecular markers associated with TSE infection in hamsters (Bolton, McKinley et al. 
1982; Collins, Lawson et al. 2004).  It was later identified in a wide range of species, 
from fish (Favre-Krey, Theodoridou et al. 2007) to birds (Gabriel, Oesch et al. 1992), to 
turtles (Simonic, Duga et al. 2000).  The protein is expressed in a number of organ 
systems, though is greatest in neuronal tissues (Collins, Lawson et al. 2004).  The 
physiologic function of the prion protein is unknown, though has been proposed to be 
involved in heavy metal binding, specifically copper transport (Viles, Cohen et al. 1999).  
The protein is a product of the PRNP gene, which, in humans, is found on chromosome 
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20 and is approximately 15.4kb in length (Prusiner 1998).  After translation, the protein 
may be modified through the addition of various carbohydrate groups at one of two 
potential C-terminal locations (human PrP residues 181 and 197), a disulfide bond 
(linking human PrP cysteine residues 179 and 214) along with a C-terminal GPI anchor 
as mentioned above (Rudd, Merry et al. 2002).  Addition of carbohydrate groups results 
in three predominant forms of the prion protein identifiable on western blotting: an 
unglycosylated isoform of approximately 27kD, a 29kD monoglycosylated isoform, and a 
36kD diglycosylated isoform (Segarra, Lehmann et al. 2009). The N-terminus of the 
protein contains an octapeptide repeat region and is relatively unstructured, while the C-
terminus has a more defined, α-helix-rich structure (Prusiner 1998).  Several 
polymorphisms have been identified in the human prion protein, which may confer either 
resistance or susceptibility to prion infection.  Of these, a methionine – valine 
polymorphism at human residue 129 has been shown to be important in sporadic, 
iatrogenic, and BSE-linked CJD (Goldfarb, Brown et al. 1994; Windl, Dempster et al. 




Figure I-1.  Primary structure of the human prion protein.  Locations of various regions 
contributing to disease susceptibility or resistance, including octapeptide repeats and 
various amino acid polymorphisms, are indicated.  Adapted from Collins, Lawson, and 
Masters. (Collins, Lawson et al. 2004) 
 
 In cervids, the expressed prion protein is composed of approximately 232 amino 
acids, and, like other species, has three distinctly glycosylated isoforms (Jewell, Conner 
et al. 2005; Kelly, Mateus-Pinilla et al. 2008).  The predominant isoform in cervids is 
diglycosylated, with the mono- and unglycosylated isoforms less abundant to varying 
degrees.  As with humans and other prion-susceptible species, the prion protein of mule 
and white-tailed deer has a number of polymorphisms.  Emerging as the most important 
of these, relative to susceptibility, is residue 96, which may be either glycine or serine 
(Johnson, Johnson et al. 2003; Jewell, Conner et al. 2005; Meeker, Ye et al. 2005; Haley, 
Seelig et al. 2009).  A number of other residues have also been shown to be variable in 
cervids, including residue 132 in elk (Green, Browning et al. 2008), 209 in moose 
(Baeten, Powers et al. 2007), 138 in caribou (Happ, Huson et al. 2007), and 226 in Sika 
deer (Meng, Zhao et al. 2005), though the significance of these polymorphisms and their 
relationship to susceptibility is unknown.  The cervid prion protein sequence shares an 
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approximately 89% amino acid identity with the human prion protein; this difference is 
thought to be significant enough to confer human resistance to infection with cervid-
origin infectious prion proteins (Kong, Huang et al. 2005).        
 
Origins of, and cell types involved in, prion shedding and horizontal transmission: 
Saliva and urine have been shown to play major roles in the transmission and diagnosis 
of a number of emergent infectious diseases, from HIV to henipaviruses (Ewing, Scorpio 
et al. 1994; Ruhl-Fehlert, Brem et al. 2000; Ersin, Kocabas et al. 2004; Aguilar-Setien, 
Loza-Rubio et al. 2005; Amado, Villar et al. 2006; Saito, Alfieri et al. 2006; Slots, 
Saygun et al. 2006; Pant Pai 2007; Wacharapluesadee and Hemachudha 2007).  
Alarmingly, though, the role of these bodily fluids in prion diseases has not been 
thoroughly evaluated.  Prior to the research described in this study, the true role of urine 
and saliva in CWD transmission, as well as its origins in these fluids, was unknown.  It 
still remains to be shown if infectious PrPres is associated with cells in these bodily fluids, 
as prion proteins – either proteolytically cleaved from the cell membrane or present in 
exosomal fractions (Parkin, Watt et al. 2004; Robertson, Booth et al. 2006; Zhao, 
Klingeborn et al. 2006) – may be found in cell-free preparations of excreta (Gatti, 
Metayer et al. 2002; Yakovleva, Janiak et al. 2004; Maddison, Whitelam et al. 2007).  In 
situ and bioassay studies have identified PrPres in lingual nerve fibers, epithelial cells, 
taste buds, and salivary glands, any or all of which may be involved in prionsialia 
(Hadlow, Eklund et al. 1974; Mulcahy, Bartz et al. 2004; DeJoia, Moreaux et al. 2006; 
Vascellari, Nonno et al. 2007).  Immune effector cells that have been implicated in prion 
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replication, e.g. lymphocytes, have been demonstrated in salivary preparations (Shugars, 
Slade et al. 2000; Shugars, Patton et al. 2001), and could be involved as carriers in the 
natural transmission of prion diseases.  Epithelial cells, the predominant cell type present 
in saliva (Xie, Onsongo et al. 2007), have also been hypothesized to be involved in prion 
disease transmission(Pammer, Suchy et al. 1999; Pammer and Tschachler 2002), though 
there is no evidence for its role in prionsialia.  In renal tissues, protease-resistant prion 
protein has been localized to the renal papillae, collecting ducts, and ectopic lymphoid 
tissue in scrapie and CWD models (Hamir, Kunkle et al. 2006; Siso, Gonzalez et al. 
2006; Ligios, Cancedda et al. 2007), while we have found PrPC heavily expressed in 
cervid transitional epithelial cells of the urinary bladder and urethra.  Any of these tissues 
and cell types may be involved in prionuria to some extent, though it has also been 
postulated that leukocytes – specifically dendritic cells – excreted during the course of 
nephritis, may be the source of infectivity (Seeger, Heikenwalder et al. 2005; Murayama, 
Yoshioka et al. 2007).  Definitive identification of the fluids, tissues, and associated cell 
type(s) involved in the natural routes of prion transmission will provide valuable 
information applicable to the pathogenesis, transmission, and diagnosis of prion diseases.   
  
Natural history of Chronic Wasting Disease: 
CWD was first recognized as a distinct disease of captive mule deer in Colorado in 1967 
(Williams and Young 1992).  Identification of CWD as a TSE was made on the basis of 
the characteristic microscopic brain lesions 11 years later, in 1978 (Williams and Young 
1980).  In the time since its initial discovery and description, CWD has been identified in 
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captive and free-ranging cervid populations in Wyoming, Nebraska, Montana, Oklahoma, 
South Dakota, Wisconsin, Minnesota, Kansas, New Mexico, Utah, Illinois, West 
Virginia, New York, Michigan, Virginia, Missouri, Alberta, Saskatchewan, and Korea 
(Sohn, Kim et al. 2002).  CWD is unique among prion diseases in that it is the only TSE 
known to infect free-ranging populations and is aggressively transmitted among and 
between cervid species (Williams and Young 1992; Miller, Williams et al. 2000).  The 
natural routes of CWD transmission have yet to be fully elucidated, though infection has 
been demonstrated following exposure to contaminated environments (Miller, Williams 
et al. 2004), and more importantly to both blood and saliva from CWD-infected deer 
(Mathiason, Powers et al. 2006).  Though urine and feces were not initially shown to 
transmit infection, the sensitivity of transgenic mouse bioassay and protein misfolding 
cyclic amplification have retrospectively allowed for the identification of CWD prions in 
both inoculated animals and in urine itself (Haley, Mathiason et al. 2009; Haley, Seelig et 
al. 2009).  On this basis, and with an incomplete scientific underpinning, every state, 
Canadian province, and member of the European Union have implemented strict 
importation restrictions on live cervids, their byproducts and biological fluids (European 
Parliament; House; Resources; www.promedmail.org; 2007). The identification of prions 
in bodily fluids, once thought not to occur, has profound impact on our understanding of 






Human exposure to CWD: 
It is evident that CWD has been present in wild cervid populations of northern Colorado 
and southern Wyoming for at least 40 years, though potentially there has been a low level 
of endemnicity for much longer (Miller, Williams et al. 2000).  The prevalence of CWD 
varies depending on species and locale, but the most recent data indicates that it can be as 
high as 30% in some areas of Colorado, and much higher in captive populations 
(Williams 2005; Keane, Barr et al. 2008; Patton, Swanson et al. 2008).  As surveillance 
efforts intensify, CWD continues to be identified in areas previously thought to be free of 
infection, including recent discoveries in a number of states east of the Mississippi River.  
Thus it is probable that substantial human exposure has occurred in the growing endemic 
area since its discovery.  Human exposure to CWD may occur directly, as occurs when 
hunters, game processors, and wildlife agents field dress, butcher, collect samples from, 
preserve, dispose of, or consume cervids and their products.  Recent cases have shown 
that the number of individuals that come in contact with an infected deer may range from 
a single person and their family, as was described in a study evaluating the likelihood of 
CWD-associated CJD infection in individuals who consumed venison in Wisconsin 
(2003), to as many as 350 individuals, as occurred during a sportsmen’s feast in New 
York (www.promedmail.org; Garruto, Reiber et al. 2008).  In Colorado, over 320 hunter-
killed deer, elk, and moose were identified as CWD positive by the Colorado Department 
of Wildlife between 2005 and 2007 (CDOW 2007), while in Wisconsin, over 1030 CWD 
positive hunter-killed animals have been identified since the disease’s initial discovery 
(WDNR 2007).  At minimum, these figures translate to thousands of individuals directly 
exposed to CWD over the past half-decade, with potentially tens of thousands more 
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exposed following consumption or handling.  Because of the likelihood of environmental 
transmission and persistence of CWD, human exposure to CWD in the environment may 
also occur; however, there are no data available by which to estimate this level of 
exposure.  
 
Potential association of human neurologic disease with CWD: 
With the apparent transmission of BSE to humans after consumption of infected material, 
and the expanding distribution of and human exposure to CWD, concerns over the 
possible zoonotic transmission of CWD to humans are growing (Bosque 2002).  At 
present, there is very little information to support or refute a link between CWD and 
human neurologic diseases, while its clinical manifestations in humans are difficult to 
predict.  Three investigations into eight cases of atypical CJD in the United States could 
not rule out the potential for a role of CWD in human illness, as experimental studies, 
(e.g. infectivity assays or glycoform analysis) were not performed (Belay, Gambetti et al. 
2001; 2003; Belay, Maddox et al. 2004; Xie, O'Rourke et al. 2006; Anderson, Bosque et 
al. 2007).  A study in transgenic mice expressing the human prion protein failed to 
demonstrate susceptibility of these animals to CWD infection, although a very limited 
number of animals, genotypes, and CWD isolates were examined without the benefit of 
secondary passage experiments (Kong, Huang et al. 2005). To more completely evaluate 
a link between CWD and human neurologic disease, continued retrospective analysis of 
atypical CJD cases, as well as prospective studies following individuals known to have 
consumed or handled CWD infected materials, need to be performed (Garruto, Reiber et 
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al. 2008).  Other emerging diagnostics, including protein-misfolding cyclic amplification, 
may prove a useful surrogate whilst these studies are undertaken (Soto, Saborio et al. 
2002; Kurt, Perrott et al. 2007; Haley, Mathiason et al. 2009). 
   
Economic impact of CWD: 
Estimating the present or potential economic impact of CWD across the nation is difficult 
given the absence of research specifically evaluating the impact of CWD on local, state, 
or national economies.  Several factors must be considered when attempting to estimate 
CWD impact, including 1) economic losses from unsold hunting licenses, equipment, and 
related expenditures, 2) the estimated value of natural resources embodied by cervid 
populations and the actual value of captive animals, and 3) cost of resources diverted to 
containment, management, and eradication of CWD (Seidl 2003; 2007).  As an example, 
the Wisconsin Department of Natural Resources estimates it has spent over $20 million 
since 2002 on surveillance, management and eradication efforts, and plans to spend an 
additional $5 million yearly toward management (Rolley 2005).  Others have speculated 
that Wisconsin’s potential economic loss, as a result of lost hunting-related expenditures 
alone, approaches $100 million annually (Bishop 2002).  These costs, however, are trivial 
when compared to the estimated $1 billion dollar impact deer hunting has on Wisconsin’s 
annual economy, or the estimated $22.6 billion spent yearly across the country on 
hunting-related activities (Rolley 2005; 2007). These estimates of course do not take into 
account the national and international economic impact should a single instance of trans-
species CWD transmission to cattle or humans occur. 
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Development of in vitro prion detection assays: 
The level of infectious prions in early infection and various non-neural tissues and bodily 
fluids has been demonstrated to be beyond the limits of detection in traditional assays, 
e.g. western blotting, immunohistochemistry, and ELISA (Head, Kouverianou et al. 
2005; Mathiason, Powers et al. 2006).  For this reason, a diagnostic aide with sensitivity 
approaching that of polymerase chain reaction (PCR) has long been sought.  In 2001, a 
technique was identified which seemed to approach the power of PCR in amplifying 
extremely low levels of PrPres seed in a sample (Saborio, Permanne et al. 2001).  This 
assay, known as protein-misfolding cyclic amplification, or PMCA (Saborio, Permanne 
et al. 2001; Soto, Saborio et al. 2002; Soto, Anderes et al. 2005), has been used in the 
detection of prions in a number of TSE’s, including hamster models of scrapie, bovine 
spongiform encephalopathy in cattle, vCJD in humans, and CWD (Castilla, Saa et al. 
2005; Soto, Anderes et al. 2005; Pastrana, Sajnani et al. 2006; Saa, Castilla et al. 2006; 
Jones, Peden et al. 2007; Kurt, Perrott et al. 2007; Murayama, Yoshioka et al. 2007; 
Murayama, Yoshioka et al. 2007; Weber, Giese et al. 2007; Haley, Mathiason et al. 2009; 
Haley, Seelig et al. 2009).  PMCA takes advantage of the conversion of the normal 
cellular prion protein, PrPC, by a seed of infectious prion material, in vitro. (Figure I-2) 
Suspect samples are incubated with aliquots of normal brain homogenate (NBH), 
interspersed with short bursts of sonication.  In the most commonly employed method, 
thirty minutes of incubation is followed by a 40-second period of sonication; this 
constitutes one cycle of amplification (Saborio, Permanne et al. 2001; Castilla, Saa et al. 
2005; Castilla, Saa et al. 2006; Haley, Mathiason et al. 2009; Haley, Seelig et al. 2009).  
Typically, samples undergo roughly 96 cycles of amplification over 48 hours, which 
 
comprises a single round of PMCA.  The homogenates may then be either ana
western blot, or serially transferred to a new preparation of NBH for further rounds of 
amplification (sPMCA).  Recently, a limitation of sPMCA in a scrapie model has been 
reported – i.e. the apparent stochastic “spontaneous generation” of proteas
prion material following many rounds of amplification.  The distinction between 
contamination and spontaneous generation has been argued and can of course be 
problematic (Agrimi, Cosseddu et al. 2008; Soto, Barria et al. 2008)
emphasize the paramount importance of appropriate control





Figure I-2: Schematic overview of PMCA
from Saborio et al. and Telling). 





 A number of other promising assays are currently under development in various 
research institutions around the world.  While it has not received the widespread attention 
that PMCA has, a method known as quaking
12 
, which serves to 
s in all PMCA experiments, 










strong potential for in vitro diagnostic capabilities (Atarashi, Moore et al. 2007).  To date, 
not much is known about the specificity of the assay, though the sensitivity is comparable 
to that of sPMCA (Ryou and Mays 2008).  The conformation-dependent immunoassay 
(CDI) is another assay showing promise in the sensitive and specific differentiation of 
infectious prion proteins (Safar, Scott et al. 2002; Safar, Geschwind et al. 2005); while a 
number of other diagnostics relying on differential conformation and substrate binding 
are under continual development. (Reviewed by Aguzzi et al. (Aguzzi, Heikenwalder et 
al. 2004)) 
 
Questions surrounding CWD upon which this dissertation is focused: 
This thesis seeks to address several unanswered questions uncovered during the 
course of research into CWD transmission, including: (1) what is the role of urine and 
saliva in the facile transmission of CWD in nature, (2) could a developing prion 
amplification assay, sPMCA, be used to identify CWD prions in tissues and bodily fluids 
of CWD-exposed cervids, and (3) what are the proximal sources of CWD prions in 
bodily fluids?  To address these questions, I first evaluated the infectious potential of 
cervid urine and saliva in a transgenic [CerPrP] mouse bioassay.  I next developed and 
optimized an in vitro prion amplification assay (sPMCA) for the detection of 
conventionally imperceptible levels of PrPCWD in clinical samples and used this assay to 
probe bodily fluids and tissues for amplifiable CWD prions.  It is my belief that the 
studies described herein enhance our current knowledge of CWD transmission and 
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pathogenesis, and provide an alternative to lengthy mouse bioassay experiments for the 
detection of low-level prion concentrations.  
 
Dissertation Research: 
The above background of TSE and CWD research formed the basis upon which 
the specific aims of this dissertation are based.  My first objective was to evaluate urine 
and saliva samples from terminal, CWD+ deer in both a sensitive Tg[CerPrP] bioassay as 
well as the newly developed sPMCA assay.  Though cervid-origin saliva was previously 
shown to harbor infectious CWD prions in cervid bioassay, the susceptibility of 
Tg[CerPrP] mice to saliva was unknown.  Conversely, cervid bioassay failed to 
demonstrate infectious prions in urine from infected deer; the potentially enhanced 
sensitivity of Tg[CerPrP] bioassay may therefore prove more useful for identifying CWD 
prions in urine.  An optimized serial PMCA assay, on the other hand, could preclude the 
need for lengthy and expensive mouse bioassay of these fluids altogether.  To address 
this first objective, I inoculated groups of mice with pooled saliva or urine from 
terminally-infected deer and allowed them to progress to terminal disease.  At that time, 
all mice were evaluated for definitive TSE infection using specific IHC, western blotting, 
and sPMCA.  Concurrently, the pooled saliva and urine samples were assessed for 
amplifiable PrPCWD by sPMCA.  I hypothesized that both transgenic [CerPrP] bioassay 
and sPMCA would be able to demonstrate PrPCWD in saliva as well as urine.    
My findings in the first objective – that both urine and saliva conferred infection 
in mouse bioassay experiments and that sPMCA could amplify PrPCWD in urine – led me 
to reconsider the negative results originally obtained in cervid urine and feces bioassay 
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experiments.  Perhaps the dose of CWD prions in urine or feces was too low to result in 
infection following oral inoculation; alternatively the initial study deer were subclinically 
infected and were sacrificed prior to fully developing clinical and pathological signs of 
infection.  Therefore, my second objective was to thoroughly evaluate these deer for 
evidence of CWD infection using the enhanced sensitivity of Tg[CerPrP] bioassay and 
sPMCA.  I hypothesized that the enhanced sensitivity of mouse bioassay and sPMCA 
would reveal that these deer were truly infected with levels of PrPCWD, below the level of 
conventional detection assays, and that the centripetal dissemination of CWD prions to 
the central nervous system would parallel that of conventionally CWD+ animals exposed 
orally to saliva.   
Finally, while I was able to conclusively demonstrate transmissible CWD prions 
in urine and saliva, as well as in deer orally exposed to urine and feces, the manner in 
which infectivity arises in these excreta remains unknown.  For this reason, the third 
objective of this work was to investigate tissues involved in urine and saliva production 
and excretion by using serial PMCA to evaluate salivary gland, tongue, kidney, ureter, 
and urinary bladder for amplifiable PrPCWD.   I hypothesized that PrPCWD could be 
amplified in these tissues, and that tissue distribution patterns would correlate with both 
route and source of inoculation as well as apparent central nervous system burden.     
The results of this work demonstrate (1) the key role of both urine and saliva in 
the facile transmission of CWD in nature, (2) the responsibility of various organs and 
tissues in the centripetal spread of CWD to the central nervous system and the shedding 
of infectious prions into these fluids, and (3) the utility of both a transgenic [CerPrP] 
mouse bioassay system and a novel amplification assay – sPMCA – in the sensitive 
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detection of low levels of PrPCWD.  For these reasons, it is my belief that this work 
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 Chronic wasting disease (CWD) is a prion disease affecting captive and free-
ranging cervids (e.g. deer, elk, and moose). The mechanisms of CWD transmission are 
poorly understood, though bodily fluids are thought to play an important role.  Here we 
report the presence of infectious prions in the urine and saliva of deer with chronic 
wasting disease (CWD).  Prion infectivity was detected by bioassay of concentrated, 
dialyzed urine and saliva in transgenic mice expressing the cervid PrP gene (Tg[CerPrP] 
mice).  In addition, PrPCWD was detected in pooled and concentrated urine by protein 
misfolding cyclic amplification (PMCA).  The concentration of abnormal prion protein in 
bodily fluids was very low, as indicated by: undetectable PrPCWD levels by traditional 
assays (western blot, ELISA) and prolonged incubation periods and incomplete TSE 
attack rates in inoculated Tg(CerPrP) mice (373±3days in 2 of 9 urine-inoculated mice 
and 342±109 days in 8 of 9 saliva-inoculated mice).  These findings help extend the 
understanding of CWD prion shedding and transmission and portend the detection of 










 Chronic wasting disease (CWD) is an efficiently transmitted prion disease of 
cervids (e.g. deer, elk, and moose) and is the only prion disease affecting free-ranging, 
non-domestic animals.  The origins of CWD are uncertain, but the disease has been 
present in wild cervid populations of northern Colorado and southern Wyoming for at 
least 40 years (Williams and Young 1980; Williams and Young 1982).  Since its 
discovery, CWD has been identified in captive and free-ranging cervids in 15 states, 2 
Canadian provinces, and Korea (Sigurdson 2008).  As surveillance efforts have 
intensified, CWD has been detected in areas previously thought to be free of infection, 
including recent discoveries in West Virginia, New York, and Michigan. The prevalence 
of CWD varies across North America, but can be as high as 30% in some areas of 
Colorado (Williams 2005).   
 
 The mechanisms of CWD transmission are not well understood, although there is 
evidence that infection is transmitted horizontally and can be acquired from 
environmental sources (Miller, Williams et al. 2004; Mathiason, Powers et al. 2006), 
which underlies the assumption that shedding of infectious prions must be significant.  
With the expanded recognition of the disease across the continental United States, it is 
also likely that substantial human exposure has occurred.  Nevertheless, because of an 
apparently strong species barrier (Kong, Huang et al. 2005) and the as yet incompletely 
understood natural routes and kinetics of CWD transmission, the magnitude and 




 Infectious CWD prions have been detected in saliva and blood, e.g. “prionsialia” 
and “prionemia,” suggesting a role for specific body fluids in transmission and 
dissemination (Mathiason, Powers et al. 2006).  In these bioassay studies in deer, 
infectivity in urine and feces could not be demonstrated, seemingly at odds with indirect 
evidence for environmental persistence of CWD prions (Williams and Young 1992; 
Miller, Williams et al. 2004).  In that the presence of prions in body fluids, once thought 
not to occur, now has impact in understanding of prion transmission and biocontainment, 














MATERIALS and METHODS 
Cervid sources:   
 Samples of urine and saliva were collected at terminal disease from five 
experimentally infected white-tailed deer.  Deer in this cohort had been inoculated 
intracranially with brain, intravenously with blood, or orally with saliva from CWD-
infected deer.  All source deer were in the terminal stages of CWD infection, and 
demonstrated moderate to severe neurologic signs, paradoxical polyphagia with declining 
body condition, polydypsia and polyuria, and were confirmed CWD+ by western blot and 
immunohistochemistry, as previously described (Mathiason, Powers et al. 2006).  
Histopathologic examination revealed mild nephritis in all the source deer.  In some 
cases, these changes were age related, while in a single case there was appreciable 
evidence of pyelonephritis.  Four of five the deer were homozygous for glycine at amino 
acid 96 of the cervid prion gene, while one deer was heterozygous at that location, with 
alleles encoding for both glycine and serine (Mathiason, Powers et al. 2006).  All animals 
were maintained in accord with Colorado State University IACUC guidelines. 
 
  Cervid PrP transgenic mice: 
 Tg[CerPrP] line 1536 (tg1536) mice were generated in the Telling laboratory at 
the University of Kentucky (Browning, Mason et al. 2004).  All mice were screened at 
weaning for the presence of the [CerPrP] construct by conventional and real-time PCR.  
All mice testing negative for PrPCWD at the completion of bioassay studies were 
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rescreened to reconfirm the presence of cervid PrP gene.  Animals were treated according 
to Colorado State University guidelines. 
 
Study samples and preparation: 
 A 1% w/v homogenate of brain from a single CWD-positive mule deer (provided 
by Dr. Michael Miller, Colorado Division of Wildlife) was used as the positive control 
material.  A 1% w/v homogenate of brain from a single CWD-negative white-tail deer 
from outside the CWD-endemic zone was used as a negative control and was provided by 
David Osborne, University of Georgia.  Urine and saliva samples were collected from 
five symptomatic whitetail deer as described above.   
  
 Spiked positive and negative control samples consisted of 1% homogenates of 
positive or negative deer brain prepared using 10ml of negative control saliva or urine as 
diluent.  For the study groups, 10mls of either urine or saliva were collected from each of 
five symptomatic deer, 50ml total volume, and homogenized.  All urine and saliva 
homogenates were then prepared for bioassay by lyophilization followed by resuspension 
in 0.1 volumes of phosphate-buffered saline (PBS) (e.g. a 10-fold concentration) and 
dialyzed against 2000 volumes of PBS to return the sample to isotonicity.   
 
Mouse bioassays: 
 Mice were anesthetized with ketamine and xylazine and inoculated intracerebrally 
into the left parietal lobe with 30µl of inoculum.  Incubation time was defined as the 
number of days from inoculation to the onset of clinical neurological signs consistent 
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with a TSE (Carlson, Kingsbury et al. 1986).  Animals were euthanized when either a 
symptomatic TSE or signs of distress were evident.  Brains were harvested at necropsy 
and divided longitudinally, with one half prepared for evaluation by western blotting and 
PMCA, while the remaining half was fixed in 10% neutral-buffered formalin for 
histopathology and immunohistochemistry. 
 
Western blotting (WB): 
 Brain tissue was initially prepared as a 10% (w/v) suspension in homogenization 
buffer (150mM NaCl, 5mM EDTA, and 1%[v/v] triton-X 100 in PBS).  Eleven µl of 
sample homogenate were mixed with 7µl of sample buffer (0.1% [v/v] triton-X 100 and 
4%(w/v) SDS in PBS) and digested with 2µl proteinase-K at 500µg/ml (final 
concentration: 50µg/ml) for 20’ at 37ºC followed by 10’  at 45ºC.  Seven µl of 4X 
running buffer were then added to the sample, followed by denaturation for 5’ at 95ºC.  
Twenty µl of this preparation were run on a pre-cast 12% SDS-PAGE gel (Invitrogen) in 
a Bio-Rad electrophoresis apparatus for 2 hours at 110mV.  Samples were then 
transferred to a PVDF membrane for 1 hour at 110mV in a Bio-Rad transfer apparatus.  
PVDF membranes were subsequently blocked for 1 hour in 5%(w/v) powdered milk in 
TBST, followed by application of the primary antibody, BAR224-HRP, diluted 1:20,000 
in 5% powdered milk in TBST, for 1 hour.  Following washing, immunoreactivity was 
detected using an enhanced chemiluminescent detection system (ECL-plus, Amersham 





Histopathology and Immunohistochemistry (IHC): 
 Cervid renal tissues and tg1536 neural tissues were fixed in formalin overnight, 
treated with 88% formic acid for one hour, washed in tap water for two hours, and then 
stored in 60% ethanol prior to paraffinization.  Paraffin-embedded tissue sections (6µm) 
were mounted onto positively charged glass slides, deparaffinized, and rehydrated 
through graded ethanol.  Tissues were subjected to Heat Induced Epitope Retrieval 
(HIER) using an automated antigen-retrieval system (Retriever™) and a proprietary 
buffer solution (DakoCytomation Target Retrieval Solution, DAKO, Hamburg, 
Germany).  Tissues were then stained with an automated immunostainer, using PrP 
monoclonal antibody BAR-224 conjugated to HRP as the primary antibody (1:250 final 
dilution).  Detection was completed using HRP-mediated hydrogen peroxide 
immunostaining (AEC+, DAKO), with haematoxylin as a counterstain.   
 
Serial Protein Misfolding Cyclic Amplification (sPMCA): 
 Source inocula as well as mice negative for PrPCWD by both WB and IHC were 
further analyzed by PMCA.  The amplification protocol, described below, was similar to 
those described by Soto and colleagues (Saborio, Permanne et al. 2001; Soto, Saborio et 
al. 2002). Normal brain homogenate (NBH), the substrate for prion conversion in vitro, 
was prepared in a room that had not previously been used for prion research as follows: 
naïve tg1536 mice were euthanized intraperitoneally with 15mg of sodium pentobarbital 
and perfused with 25ml of 5mM EDTA in PBS via intracardiac catheterization.  The 
calvarium was removed and the entire brain excised and placed on ice.  Brain 
homogenate was then prepared at a 10% (w/v) solution in PMCA buffer (1% triton-X 100 
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[v/v], 5mM EDTA, 150mM NaCl, and 0.5% saponin [w/v] in PBS adjusted to a pH of 
7.2) with the addition of Complete Protease Inhibitors (Roche Pharmaceuticals, 
Indianapolis, IN) in a dounce homogenizer.  Homogenates were then centrifuged for 1 
minute at 2000rpm to remove bulk brain material, and the supernatant frozen in single-
experiment aliquots at –70ºC in a “prion-free” room until use in PMCA.  Experimental 
handling protocols were identical to protocols commonly used for PCR: NBH was added 
to a plate in a room not previously used for prion research and then transferred to a room 
used exclusively for prion research, where samples were added in a biosafety hood prior 
to sonication.  Twenty-five µl of either source inocula or WB and IHC negative brain 
homogenate was added to 25µl of NBH in individual wells of a 96 well PCR plate (USA 
Scientific, Ocala, FL), placed in an ultrasonic processor (Misonix, Farmingdale, NY) and 
incubated at 37ºC.  Samples were sonicated for 40s at power setting 7.0, followed by 30 
minutes of incubation.  Ninety six cycles of sonication were preformed over 48 hours, 
with a 25µl aliquot transferred to a fresh NBH preparation for serial amplification.  
Following three rounds of amplification, samples were evaluated by western blotting, as 









 To investigate whether urine may play a role in natural CWD transmission, and to 
confirm the presence of PrPCWD in saliva, pooled and concentrated urine or saliva from 
five terminally infected CWD+ deer was inoculated into two groups of tg1536 mice.  
Following inoculation, mice were monitored for clinical signs of prion infection and were 
euthanized when terminal disease was apparent.  Central nervous system tissues were 
evaluated for PrPCWD using western blotting (WB), immunohistochemistry (IHC) and, 
when negative by conventional assays, serial protein misfolding cyclic amplification 
(sPMCA). 
 
 In a group of 9 mice inoculated with lyophilized urine, 2 animals developed 
neurologic disease consistent with a TSE (Table 1.1), including ataxia, a slow, lumbering 
gait, and poor thrift, at 370 and 376 days post-inoculation (dpi).  Eight out of 9 mice 
inoculated with prepared saliva likewise developed signs of TSE at 342+/-109 dpi.  All 
mice in positive control groups, inoculated with CWD+ brain spiked into either urine or 
saliva, developed disease before 370 dpi (235+/-91dpi), while none of the mice in either 
negative control group, inoculated with either urine or saliva spiked with negative brain 





Table 1.1: Western Blot (WB), immunohistochemistry (IHC), and protein-misfolding 
cyclic amplification results and incubation periods of Tg[CerPrP] mouse bioassay.  
Numerators indicate the number of animals testing positive by a particular assay, while 
denominators designate the total number tested.  PMCA analysis was reserved for mice 
testing negative by traditional assays.  Incubation periods indicate the survival times in 
days post inoculation +/- one standard deviation.     
 
Mouse bioassay of saliva and urine reveal the presence of infectious CWD prions: 
 Brains of all mice demonstrating terminal neurologic disease, including 2 of 9 
inoculated with urine and 8 of 9 inoculated with saliva, had evidence of protease-resistant 
prion protein by both WB and IHC.  PrPCWD was absent by both WB and IHC in mice not 
displaying clinical disease, including those in negative control groups.    
  
 Immunohistochemistry demonstrated widely distributed, florid PrPCWD plaques, 
with no apparent relationship between deposition pattern, lesion severity, and source 
inoculum (Figure 1.1).  In cases with the least severe pathology, however, cortical lesions 
predominated; with increasing neuropathology, lesions were further distributed within the 
hippocampus, midbrain, and cerebellum. 
 
 
Figure 1.1: Spongiform degeneration and PrP
immunohistochemistry.  Vacuolated neurons and spongiform degeneration of the 
neuropil characteristic of a TSE is evident on H&E staining, with the colocalization of 
PrPCWD specific immunostaining of florid plaques in the c
positive control inoculum and concentrated urine and saliva from CWD
Negative control mice showed no evidence of spongiform degeneration or PrP
immunostaining.  HRP-conjugated BAR
bar, 50 µm)  
 
 In western blotting, PrP
In all cases, the dominant PrP
mono- and non-glycosylated isoforms (Figure 1.2).
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Figure 1.2: Western Blot detection of PrPCWD in urine and saliva-inoculated mice.  
Western blotting analysis of control and test mice, demonstrating PrPCWD in positive 
control mice (lanes 1 and 2), as well as urine (lanes 3 and 4) and saliva (lanes 5 and 6) 
inoculated mice.  Protease-resistant prions were not detected in negative control mice 
(lanes 7 and 8).  Flanking lanes represent undigested PrPC. 
 
Cervid urine donors display evidence of renal pathology on histological evaluation: 
 To identify potential pathological mechanisms for prionuria, histopathologic 
examination of donor renal tissues was also performed.  Microscopic evaluation of H&E 
stained kidney sections from each of the donor deer revealed minimal histologic disease 
in 4 of the 5 animals.  Lesions in these animals were characterized by the combination of 
minimal proliferative glomerular disease and mild interstitial fibrosis and lymphocytic 
inflammation (Figure 1.3A and B).  In these animals, there was no appreciable histologic 
evidence of proteinuria or pyelonephritis.  In the fifth animal, more significant renal 
pathology was detected.  In this animal, there was a combination of mild, chronic, 
lymphocytic glomerulonephritis, which was similar to the previous 4 animals, and a 
moderately severe, chronic, lymphocytic interstitial nephritis with light microscopic 
evidence of renal protein loss (“tubular proteinosis”). (Figures 1.3C and D) 
 
Figure 1.3: Histopathologic evaluation of renal tissues from donor cervids.  (A)
chronic and proliferative glomerular disease and (B) mild interstitial fibrosis and 
lymphocytic infiltration were observed in 4 out of 5 donor deer.   The remaining deer 
showed evidence of mild lymphocytic glomerulonephritis (C) as well as “tubular 
proteinosis.” (D, arrows) 
 
Serial PMCA may amplify PrP
and exposed mice:  
 Concentrated samples used for mouse inoculation were assayed for PrP
serial PMCA (sPMCA) over three rounds of amplification.  In our experience, three 
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rounds of amplification permits an approximate 4000-fold increase in sensitivity as 
compared to traditional western blotting detection, while avoiding both cross-
contamination and generation of any spontaneously formed protease-resistant PrP, 
thereby maintaining 100% specificity (Kurt, Perrott et al. 2007).  In three independent 
experiments, PrPCWD was identified in lyophilized urine homogenate from CWD+ deer. 
(Figure 1.4A)  PrPCWD was also found in both positive control inocula after the initial 
round of amplification, while PrPCWD was not detected in either saliva or negative control 
preparations. 
 To increase detection sensitivity in bioassay experiments, brains from all mice 
that tested negative for PrPCWD by WB and IHC, including negative controls, were re-
evaluated by sPMCA.  The brain from one WB- and IHC-negative mouse that had been 
inoculated with urine from a CWD+ deer and expired at 582dpi amplified PrPCWD in 
three independent PMCA experiments (Figure 1.4B).  No mice in either of the negative 
control groups were positive using this assay.  
 
 
Figure 1.4. Serial PMCA 
brains of urine-inoculated mice. A)
control and urine inocula (lanes 1 and 2, respectively), while PrP
identified in saliva and ne
rounds of amplification.  B)
of CWD-infected mice, including positive
inoculated with lyophilized urine (lanes 1 and 3, respectively).  PrP
in mice inoculated with negative control material (lanes 5 and 6) or in other mice 
inoculated with either urine (lane 2) or saliva (lane 4) from CWD+ deer.  All flanking 
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 The salient feature of chronic wasting disease is its facile transmission among its 
host species.  Until recently, little was known regarding the mechanisms of this efficient 
transmissibility, however, previous research has demonstrated infectious prions in the 
saliva and blood of infected deer (Mathiason, Powers et al. 2006).  By using intracerebral 
inoculation of concentrated urine in cervid PrP transgenic mice, we report the presence of 
infectious prions in urine from CWD-infected cervids, and confirm the phenomenon of 
prionsialia in these animals.  The identification of CWD prions in bodily fluids described 
in the current report could portend infectivity in secretions and excretions in other prion 
diseases. 
   
 In contrast to the data presented here, oral inoculation of urine in cervid bioassays 
was unable to identify infectious prions in the urine of CWD+ deer (Mathiason, Powers 
et al. 2006).  This result could have been due to necessarily limited observation period 
possible in those studies (19 months), or variations in source and recipient genotype 
(Hamir, Gidlewski et al. 2006; O'Rourke, Spraker et al. 2007), route of inoculation 
(Hamir, Kunkle et al. 2005), or the sensitivity of traditional PrPCWD detection assays 
(Safar, Geschwind et al. 2005; Grassi, Maillet et al. 2008).  The mule deer providing 
inoculum pools in prior studies were of an unreported genotype; the majority of the 
recipient deer were homozygous for glycine at residue 96, although a single animal was 
heterozygous; sharing both G96 and S96 alleles (Mathiason, Powers et al. 2006).    
Likewise, the inocula used in the present study were pooled from sources heterogeneous 
at codon 96 of the cervid prion gene.  Transgenic mice used in bioassay studies, on the 
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other hand, were uniformly homogenous for a glycine residue at this position (Browning, 
Mason et al. 2004), a polymorphism which is reported to be overrepresented in CWD-
infected deer (Johnson, Johnson et al. 2003).  As a result, it is possible that the genotypic 
background of either source or subject animals may have been a factor in susceptibility, 
though at present, we are unable to draw any concrete conclusions regarding this 
relationship.   While mouse genotype may have played a role in the outcome, it is also 
probable that cervid PrP transgenic mouse bioassay simply represents a more sensitive 
detection system for prions in excreta.  Intracranial inoculation, reportedly a more 
sensitive route of prion exposure (Hamir, Kunkle et al. 2005; Hamir, Kunkle et al. 2008), 
is more easily performed in mouse bioassay, a model which also permits extended 
incubation periods and inclusion of a greater number of test animals. 
 
 While my findings point to urine as an additional vehicle for CWD transmission, 
only 2 of 9 inoculated tg1536 mice were confirmed WB/IHC-positive for prion infection, 
with a third PrPCWD+ animal later identified by PMCA.  This contrasts with 8 of 9 
positive mice receiving saliva and infers a much lower concentration of prion infectivity 
in urine.  The wide range of survival times in inoculated mice suggests relatively low 
levels of infectious prions and/or uneven distribution of infectious PrP moieties in the 
inocula (Kariv-Inbal, Ben-Hur et al. 2006).  Differing [CerPrP] zygosity in tg1536 mice 
(homozygous vs. hemizygous) may also have played a role in this variation (Browning, 




 Using sPMCA, PrPCWD was repeatedly identified in test urine and spiked urine 
and saliva used as positive control, but was not detected in test saliva after three rounds 
of amplification.  The reasons for our inability to identify PrPCWD in saliva – given the 
definitive bioassay findings – remain unknown, and we propose the presence of as-yet 
unidentified inhibitors such as mucin or salivary proteases which are thought to 
negatively affect other in vitro assays (Archibald and Cole 1990; Ochert, Boulter et al. 
1994).  
 
 The finding of PrPCWD in urine and saliva calls for the identification of the 
pathological processes and cellular associations of the prion protein involved in shedding.  
Previous studies have related renal pathology to prionuria (Seeger, Heikenwalder et al. 
2005; Siso, Gonzalez et al. 2006), a finding which corresponds to the identification of 
mild to moderate nephritis in those deer providing samples for the current study.  It is 
plausible that renal pathology contributed to prionuria in each of these animals; as 
samples were pooled, however, we cannot identify specific animals in which it may have 
been occurring, nor can we accurately estimate the relative level of prionuria occurring in 
each donor as ultrastructural studies were not performed (Nacar, Karabay et al. 2008).  
While we have not yet identified pathologic prions in renal source tissues [Unpublished 
data], protease-resistant PrPCWD has been identified by immunostaining in renal tissue of 
prion-infected deer (Hamir, Kunkle et al. 2006), sheep (Ligios, Cancedda et al. 2007), 
hamsters and most intriguingly humans (Fournier, Escaig-Haye et al. 1998), 
foreshadowing the potential for prionuria in other transmissible spongiform 
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encephalopathies.  We continue to examine tissues from CWD+ deer in an effort to 
determine the pathogenesis and kinetics of CWD prion excretion and shedding.    
 
 Evidence for excretion and shedding of infectious prions is also accumulating in 
the scrapie system.  PrPC-converting activity has been identified by sPMCA in the urine 
of scrapie-infected sheep, hamsters and mice (Kariv-Inbal, Ben-Hur et al. 2006; 
Murayama, Yoshioka et al. 2007; Andrievskaia, Algire et al. 2008; Gonzalez-Romero, 
Barria et al. 2008).  Prion infectivity has also been demonstrated in the feces of hamsters 
orally infected with scrapie (Safar, Lessard et al. 2008).  Other studies point to infectious 
prions in the milk of scrapie-infected ewes (Gresham 2008; Konold, Moore et al. 2008).  
As noted above, it remains unknown whether other prion diseases (e.g. Kuru, BSE, CJD, 
TME) may be transmitted by bodily fluids or excreta other than blood.  Additional 
studies examining feces, milk, and other body fluids are therefore necessary in CWD and 
other prion diseases, studies currently underway in our laboratory. 
 
  As CWD transmission may model communicability of other TSE’s, the 
transmissible nature of prion diseases may serve as a model for other protein-misfolding 
diseases.  For example, feces, but not urine, from both mice and cheetahs affected with 
systemic amyloidosis A (SAA) was recently shown to induce SAA in a mouse model, 
although negative controls were not available in those studies (Zhang, Une et al. 2008).  
In light of the prionuria detected in CWD and in models of scrapie, further investigations 
of infectivity in body fluids in other protein folding diseases may be warranted in the 
event that prion diseases are not the only infectious proteinopathies.  
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 In summary, we have confirmed prionsialia in CWD-affected deer by bioassay in 
cervidized mice and demonstrate for the first time infectious prions in the urine of these 
cervids by both bioassay and sPMCA.  We are currently evaluating urine and saliva from 
individual animals in hopes of identifying predisposing factors, such as genotypic 
background and underlying pathology, which may contribute to prionuria and prionsialia.  
Concurrently, we have begun to explore the tissue origins and protease sensitivity of the 
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Detection of Subclinical CWD Infection in Conventional Test-Negative Deer Long After 















 Chronic wasting disease (CWD) of cervids is a prion disease distinguished by its 
high level of transmissibility, wherein bodily fluids and excretions are thought to play an 
important role.  Using cervid bioassay and established CWD detection methods, 
experiments have previously identified infectious prions in saliva and blood but not urine 
or feces of CWD+ donors.  More recently, our research has identified very low 
concentrations of CWD prions in urine of deer by cervid PrP transgenic (Tg[CerPrP]) 
mouse bioassay and serial protein misfolding cyclic amplification (sPMCA).  This 
finding led us to examine further those initial cervid bioassay experiments using sPMCA.  
We sought to determine whether deer previously exposed orally to urine and feces from 
CWD+ sources, while conventional test-negative, may actually be harboring very low 
level CWD infection not evident in the 19 month observation period in the previous 
studies.  We further attempted to trace the centripetal spread of PrPCWD in these animals 
from the gastrointestinal tract to the central nervous system in these animals.  Obex, vagal 
nerve, intermediolateral spinal cord segments, sections of ileum, and a wide range of 
lymphoreticular system (LRS) tissues from conventional test-negative deer were 
reanalyzed for CWD prions by sPMCA and cervid transgenic mouse bioassay in parallel 
with appropriate tissue-matched positive and negative controls.  PrPCWD was detected in 
the tissues of orally exposed deer by both sPMCA and Tg[CerPrP] mouse bioassay; each 
assay revealed very low levels of CWD prions previously undetectable by western blot, 
ELISA, or IHC.  Serial PMCA analysis of individual tissues identified that obex alone 
was positive in urine/feces exposed deer. PrPCWD was amplified from both LRS and 
neural tissues of positive control deer but not from the same tissues of negative control 
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deer.  Detection of subclinical infection in deer orally exposed to urine and feces, (1) 
suggests that a prolonged subclinical state can exist such that observation periods in 
excess of two years may be needed to detect CWD infection, and (2) illustrates the 
sensitive and specific application of sPMCA in the diagnosis of low-level prion infection.  
Based on these results, it is possible that low doses of prions,  such as via oral exposure to 
urine and saliva of CWD-infected deer, bypass significant amplification in the LRS, 
perhaps utilizing a neural conduit between the alimentary tract and central nervous 















 Chronic wasting disease (CWD) is an efficiently transmitted prion disease of 
cervids (e.g. deer, elk, and moose), and is the only known prion disease affecting free-
ranging, non-domestic animals.  The origins of CWD are uncertain, but the disease has 
been present in wild cervid populations of northern Colorado and southern Wyoming for 
at least 40 years (Williams and Young 1980; Williams and Young 1982).  Since its 
discovery, CWD has been identified in captive and free-ranging cervids in 15 states, 2 
Canadian provinces, and Korea (Sigurdson 2008).  As surveillance efforts have 
intensified, CWD has been detected in areas previously thought to be free of infection, 
including recent discoveries in West Virginia, New York, and Michigan (NYSDAM 
2005; WVDNR 2005; MDNR 2008). The prevalence of CWD varies across North 
America, but can be as high as 30% in some areas of Colorado or in captive populations 
(Williams 2005; Keane, Barr et al. 2008).   
 
 Although the mechanisms of CWD transmission are incompletely understood, 
there is evidence inferring that infection is transmitted horizontally via saliva and urine 
(Mathiason, Powers et al. 2006; Mathiason, Hays et al. 2009), and may be acquired from 
the environment (Miller, Williams et al. 2004; Johnson, Phillips et al. 2006; Johnson, 
Pedersen et al. 2007).  With the expanded recognition of the disease across the 
continental United States, it is also likely that substantial human exposure has occurred.  
However, because of an apparently strong species barrier (Raymond, Bossers et al. 2000; 
Kong, Huang et al. 2005) and the as yet incompletely understood natural routes and 
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kinetics of CWD transmission, the magnitude and consequence of this exposure remain 
speculative.  
 
 While infectious CWD prions have been detected in saliva, blood, urine, and 
feces (i.e. prionsialia, prionemia, prionuria, and prionorrhea) conventional CWD 
diagnostic assays (e.g. western blotting, immunohistochemistry, and enzyme-linked 
immunosorbent assay) have been unable to identify PrPCWD in these materials 
(Mathiason, Powers et al. 2006; Haley, Seelig et al. 2009; Mathiason, Hays et al. 2009; 
Tamguney, Miller et al. 2009).  In the same vein, the early and antemortem identification 
of subclinically infected individuals requires demonstration of PrPCWD in biopsied 
lymphoreticular system (LRS) tissues (Wild, Spraker et al. 2002; O'Rourke, Zhuang et al. 
2003; Spraker, Gidlewski et al. 2006; Wolfe, Spraker et al. 2007).  Improving the 
sensitivity of low level of CWD prion detection in excreta or at early sites of 
accumulation may allow for earlier antemortem diagnosis and a stronger estimate of 
prevalence (Hill and Collinge 2003; Hill and Collinge 2003; Castilla, Gutierrez-Adan et 
al. 2004; Spraker, Balachandran et al. 2004; Haley, Seelig et al. 2009), an approach 
which could also aid in detection of human transmissible spongiform encephalopathies 
(TSE’s). 
 
 Apart from inoculation of susceptible hosts (bioassay), only in vitro amplification 
by serial protein misfolding amplification (sPMCA) (Saborio, Permanne et al. 2001; 
Soto, Saborio et al. 2002; Kurt, Perrott et al. 2007; Haley, Seelig et al. 2009) offers the 
potential for comparable sensitivity.  In these experiments, we have employed both of the 
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latter methods to demonstrate low levels of infectious prions in clinically normal, 
conventional assay-negative white-tailed deer orally exposed 19 months previously to 























MATERIALS and METHODS 
Infected cervids: 
 Five white-tailed deer (Odocoileus virginianus) were orally inoculated with urine 
(50ml total volume) and feces (50g total volume) from CWD+ donor deer.  The deer 
were monitored for 19 months post inoculation (pi), during which time they remained 
asymptomatic.  At 19 months pi, due to limitations in holding space imposed by other 
ongoing studies, the animals were euthanized, necropsied, and brain and lymphoid tissues 
examined for PrPCWD by western blotting (WB) and immunohistochemistry (IHC) 
(Mathiason, Powers et al. 2006).  The sources of the urine and feces used for inoculation 
were three terminally-ill mule deer (Odocoileus hemionus) of unknown PrP genotype.  
Three of the inoculated deer were homozygous for glycine (i.e. G/G) at cervid PrP 
position 96 (Deer #’s 134, 141, and 150), while two were heterozygous at that location 
(Deer #’s 111 and 124), with alleles encoding for both glycine and serine (G/S). Tissues 
from all five animals were negative for PrPCWD by WB and IHC and the animals were 
thus considered CWD-negative.  The same tissue sets were collected from positive and 
negative control animals, including a deer inoculated intracranially (IC) with CWD+ 
brain (deer #106, G/S at position 96), two deer inoculated per os (PO) with saliva from 
CWD+ deer (deer #113 and 122, both G/G at position 96) and three deer inoculated by 
the IC and PO routes with brain homogenate from a CWD-naive deer (deer # 103 and 
123, both G/G at position 96 and deer #4488 – G/S at this loci).  Each deer was 
necropsied using fresh necropsy instruments, and all tissue samples were frozen at -70° C 




Study samples and preparation: 
 Obex, vagal nerve, intermediolateral spinal cord segments, sections of ileum, and 
a number of lymphoid tissues, including tonsil and retropharyngeal, mesenteric, 
mediastinal, and ileocecocolic lymph nodes, were collected at necropsy and frozen at -
70°C.  In initial sPMCA and bioassay experiments, obex and retropharyngeal lymph node 
(RLN) tissues from individual animals were pooled, as both these tissues have proven 
sensitive in the identification of PrPCWD at various stages of infection (Sigurdson, 
Williams et al. 1999; Hibler, Wilson et al. 2003; Spraker, Balachandran et al. 2004; Fox, 
Jewell et al. 2006; Race, Meade-White et al. 2007; Keane, Barr et al. 2008).  In later 
serial PMCA (sPMCA) experiments, specific neural and LRS tissues were analyzed 
individually.  In each case, a fifty milligram section of each tissue was washed twice in 
phosphate-buffered saline (PBS), then homogenized and prepared as a 1% solution (w/v) 
in PBS using a FastPrep™ tissue homogenizer for 40s at power setting 6.5.  All tissues 
were prepared in individual microcentrifuge tubes and homogenized in parallel in the 
same machine concurrent with controls.     
 
Cervid PrP transgenic mice: 
 Tg[CerPrP] line 5037 (tg5037) mice were generated in the Telling laboratory at 
the University of Kentucky (Angers, Seward et al. 2009).  These mice express, both 
centrally and peripherally, an allelic variant of the prion gene possessed by Rocky 
Mountain Elk (Cervus elaphus), coding for glutamic acid at position 226 of the cervid 
prion protein.  All mice were screened at weaning for the presence of the cervid PRNP 
transgene by conventional and real-time PCR.  Mice testing negative for PrPCWD at the 
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completion of bioassay studies were rescreened to confirm the presence of cervid 
transgene.  Mice were inoculated and maintained in accord with Colorado State 
University IACUC guidelines. 
 
 Serial Protein Misfolding Cyclic Amplification (sPMCA): 
 Tissue homogenates from CWD-exposed deer, negative by WB, IHC, and ELISA, 
were assayed for PrPCWD by sPMCA.  In initial  experiments, CWD+ obex/RLN 
homogenate from a white-tailed deer IC-inoculated with CWD+ brain (deer #106) was 
used as a positive control, while tissue preparations from two sham-inoculated deer (#103 
and 123) and untreated tg5037 mice were used as negative controls.  In later experiments, 
a tissue set from a deer orally inoculated with CWD+ brain (deer #148) was selected for 
use as positive controls; negative control animals remained unchanged.  All test samples 
were prepared in parallel with tissue-matched positive and negative controls as a 1% 
homogenate in PBS as described above and subsequently spiked into normal brain 
homogenate for amplification as described previously (Kurt, Perrott et al. 2007; Haley, 
Seelig et al. 2009; Kurt, Telling et al. 2009).  Normal brain homogenate (NBH), the 
substrate for prion conversion in vitro, was prepared from tg5037 mice in a room that had 
not previously been used for prion research.  Following euthanasia and perfusion with 
5mM EDTA in phosphate-buffered saline (PBS), whole brain was collected from naïve 
tg5037 mice and placed on ice.  Brain homogenates were prepared as a 10% (w/v) 
solution in PMCA buffer (1% triton-X 100 [v/v], 5mM EDTA, and 150mM NaCl in PBS 
adjusted to a pH of 7.2) with the addition of Complete Protease Inhibitors (Roche 
Pharmaceuticals, Indianapolis, IN) using a dounce homogenizer.  Homogenates were 
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then centrifuged for 1 minute at 2000rpm and the supernatant frozen in single-experiment 
aliquots at –70ºC in a “prion-free” room until use in PMCA.  Fifteen µl of test or control 
tissue homogenate was added to 45µl of NBH and assayed, in parallel and in adjacent 
wells of a 96-well plate (USA Scientific, Ocala, FL); along with normal brain 
homogenate prepared from unexposed tg5037 mice as additional, unseeded negative 
controls.  Plates were then sonicated using an ultrasonic processor (Misonix, 
Farmingdale, NY) and incubated at 37ºC.  Sonication parameters were set at 40s bursts at 
power level 7.0, followed by 30 minutes of incubation.  Ninety six cycles of sonication 
were performed over 48 hours, with a 10µl aliquot transferred to 50µl of fresh NBH for 
serial amplification.  Following three rounds of amplification, samples were evaluated by 
western blotting, as described below, for the presence of PrPCWD.  Brain homogenates 
from all mice testing negative for PrPCWD in bioassay experiments were likewise 
analyzed to increase detection sensitivity.  In analysis of individual cervid tissue samples, 
occasional differences were noted in the round in which amplification was initially 
observed.  For this reason, we tallied the number of successive positive rounds for each 
sample in each repetition for semi-quantitative analysis.  Over the course of sPMCA 
experiments, multiple NBH preparations were used, and each test or control sample was 
evaluated at least three times for repeated verification of results.   
 
Mouse bioassays: 
 Four groups of tg5037 mice (n=8/group) were anesthetized with ketamine and 
xylazine and inoculated intracerebrally into the left parietal lobe with 30µl of 1% 
obex/RLN homogenate.  Positive control mice were inoculated with obex and RLN from 
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a deer IC-inoculated with CWD+ brain (deer #106), while a single negative control group 
was inoculated with combined obex and RLN homogenates from two sham-inoculated 
deer (deer #103 and 123).  Obex and RLN homogenates from two deer orally inoculated 
with urine and feces (deer #134 and 150) were selected for bioassay experiments based 
on their apparent amplification ability in sPMCA experiments (below).  Incubation time 
was defined as the number of days from inoculation to the onset of clinical signs of 
transmissible spongiform encephalopathy (TSE), as previously described (Carlson, 
Kingsbury et al. 1986).  Animals were euthanized when either signs of clinical TSE or 
distress were evident.  Brain harvested at necropsy was divided longitudinally, with one 
hemi-section prepared for evaluation by western blotting and sPMCA and the remaining 
hemi-section fixed in 10% neutral-buffered formalin for immunohistochemical analysis 
 
Western blotting (WB): 
 Brain hemi-sections for WB and sPMCA were initially prepared as a 10% (w/v) 
solution in PMCA buffer.  Eleven µl of sample homogenate were mixed with 7µl of 
sample buffer (0.1% [v/v] triton-X 100 and 4% [w/v] SDS in PBS) and digested with 2µl 
proteinase-K at 500µg/ml (final concentration: 50µg/ml) for 20’ at 37ºC followed by 10’  
at 45ºC.  Seven µl of 4X running buffer were then added to the sample, followed by 
denaturation for 5’ at 95ºC.  Twenty µl of this preparation were run on a pre-cast 12% 
SDS-PAGE gel (Invitrogen) in a Bio-Rad electrophoresis apparatus for 2 hours at 
120mV.  Samples were then transferred to a PVDF membrane (Millipore) for 1 hour at 
110mV in a Bio-Rad transfer apparatus.  PVDF membranes were subsequently blocked 
for 1 hour in 5%(w/v) powdered milk in 0.2% Tween-20 in tris-buffered saline (TBST), 
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followed by application of the primary antibody, BAR224-HRP, diluted 1:20,000 in 
TBST with 5% powdered milk, for 1 hour.  Following washing, immunoreactivity was 
detected using an enhanced chemiluminescent detection system (ECL-plus, Amersham 
Biosciences) in a LAS 3000 imaging system. (Fuji Photo Film, Fuji Inc, Valhalla, NY) 
 
Neuropathology and immunohistochemistry (IHC): 
 Brain hemi-sections were fixed in formalin overnight, treated with 88% formic 
acid for one hour, washed in tap water and then stored in 60% ethanol prior to 
paraffinization.  Paraffin-embedded tissue sections (6µm) were mounted onto positively 
charged glass slides, deparaffinized, and rehydrated through graded ethanol.  To enhance 
detection, tissues were subjected to Heat Induced Epitope Retrieval (HIER) using an 
automated antigen-retrieval system (Retriever™) and a proprietary buffer solution 
(DakoCytomation Target Retrieval Solution, DAKO, Hamburg, Germany).  Tissues were 
then stained with an automated immunostainer, using polyclonal PrP antibody R-505 as 
the primary antibody (a gift from Dr. Jan Langeveld, Central Veterinary Institute of 
Wageningen University), The Netherlands) at a 1:500 final dilution, followed by 
secondary application of a universal anti-rabbit polyclonal antibody conjugated to 
horseradish peroxidase (HRP).  Detection was completed using HRP-mediated hydrogen 








 To evaluate CWD-exposed, yet IHC-, and WB-negative, deer for subclinical 
CWD infection, we pooled obex and retropharyngeal lymph node (RLN) tissues in an 
effort to enhance detection sensitivity.  Pooled tissues from individual animals were 
initially analyzed via serial PMCA (sPMCA) with results subsequently confirmed in two 
of these individuals using bioassay in cervidized tg5037 mice.  Serial PMCA was then 
used to analyze individual nervous and LRS tissues to estimate the mechanism of CNS 
invasion in animals orally exposed to presumed low doses of CWD prions that may be 
present in urine and feces. 
 
Serial PMCA amplification of PrP
CWD
 from tissues of deer orally exposed to urine and 
feces:   
 Obex and RLN tissues collected at necropsy from experimentally exposed deer 
were prepared as a 1% solution in PBS and subjected to three rounds of sPMCA as 
described.  In our experience, three rounds of amplification permits up to 4000-fold 
increase in sensitivity as compared to traditional western blotting detection, while 
maintaining 100% specificity (Kurt, Perrott et al. 2007; Haley, Seelig et al. 2009).  In 
three independent experiments, obex and RLN homogenates from individual deer that 
had been orally inoculated with urine and feces from a CWD+ source (deer #’s 111, 124, 
134, 141 and 150) consistently amplified PrPCWD by sPMCA.  Positive control tissues 
from an IC-inoculated deer (deer #106) also successfully amplified PrPCWD through each 
round, while concurrently run control tissue homogenates from CWD-negative brain-
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inoculated deer (deer #’s 103 and 123) or naïve tg5037 mice were negative by sPMCA. 
(Figure 2.1)   
 
 
Figure 2.1: Serial PMCA amplification of CWD prions in WB and IHC negative deer.  
Conventionally negative tissues from deer orally exposed to urine and feces from CWD+ 
sources (Deer #’s 111, 124, 134, 141, and 150, lanes 4-8) amplified PrPCWD after 2-3 
rounds of PMCA, as did positive control tissues from deer #106 (lane 1).  Tissue samples 
from two sham-inoculated deer (#103 and 123, lanes 2 and 3) and two untreated tg5037 
mice (lanes 9 and 10) failed to amplify PrPCWD in three rounds of sPMCA.  
 
 Based on these findings, tissues from two white-tailed deer with the greatest 
apparent in vitro amplification ability (deer #134 and #150, Figure 2.1), along with 
tissue-matched controls, were selected for further evaluation by tg5037 mouse bioassay.  
Groups of mice were inoculated with obex/RLN homogenates, monitored for clinical 
signs of prion infection, and euthanized when terminal disease was apparent.  Brains 
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from inoculated mice were evaluated for PrPCWD by WB, IHC and, when negative by 
these assays, also by sPMCA. 
 
Authentic prion infectivity identified in tg5037 mouse bioassay:  
 In a group of 8 mice inoculated with obex/RLN homogenates from deer #134, 7 
of the 8 mice developed clinical signs consistent with TSE, including progressive ataxia 
and weight loss, by 264 days post inoculation (dpi).  WB and IHC confirmed the 
presence of PrPCWD in each of these seven mice.  The remaining mouse in this group died 
of intercurrent disease at 161 dpi.  This mouse showed no evidence of clinical TSE and 
was negative for PrPCWD by both IHC and WB (Figure 2.3, mouse #2-B).  In a second 
group of mice, inoculated with tissues from deer #150, 8 of 8 mice developed similar 
clinical signs of TSE infection and were confirmed PrPCWD-positive by WB and IHC by 
272 dpi.  All mice inoculated with brain and RLN homogenates from positive control 
deer #106 developed clinical TSE and were PrPCWD-positive by 173 dpi, whereas 
negative control mice remained healthy until euthanasia at 340+ dpi, at which time they 




Figure 2.2: Tg5037 mouse bioassay results. Kaplan-Meyer curve demonstrating 
prolonged incubation periods in mice inoculated with tissues from deer #134 and 150 as 
compared to mice inoculated with tissues from deer testing positive by conventional 




Table 2.1: Summary of immunohistochemistry (IHC), western blot (WB), and serial 
PMCA results and Tg5037 mouse bioassay of combined obex/RLN homogenates.  Mean 
incubation periods with standard deviations in parentheses; numerators indicate number 
of animals testing positive over total number tested.  For PMCA, only those animals 






Figure 2.3: Western blot detection of PrPCWD in mouse CNS tissues.  Except for a single 
mouse (mouse Tg 2-B, lane 4), all mice inoculated with tissues from deer #134 and 150 
succumbed to prion disease (lanes 3-7), as did mice inoculated with CWD+ deer #106 
(lanes 1 and 2).  Mice inoculated with tissues from sham-inoculated deer showed no 
evidence of PrPCWD by western blot (lanes 8 and 9).  
 
Biochemical confirmation of bioassay:  
 Western blot glycoform patterns were typical of CWD in Tg[CerPrP] tg5037 
mice, spanning  21-27 kD following proteinase-K digestion and dominated by a di-
glycosylated PrPCWD isoform.   Representative WB’s from each group are shown in 
Figure 3.  Immunohistochemistry demonstrated a relatively narrow distribution of 
PrPCWD within the hippocampus of affected mice, colocalizing with vacuolization and 
spongiform degeneration of the neuropil.  There was no apparent relationship between 






Figure 2.4: Spongiform degeneration and PrPCWD in the hippocampus of inoculated mice. 
Vacuolated neurons and spongiform degeneration of the neuropil characteristic of TSE 
demonstrated by H&E staining and co-localization of PrPCWD florid plaques in the 
hippocampus of mice inoculated with tissues from urine and feces exposed and positive 
control deer.  Brains of mice inoculated with tissues from sham-inoculated deer showed 
no evidence of spongiform degeneration or PrPCWD immunostaining.  Anti-prion 
polyclonal antibody R-505 was used as the primary antibody.  (Measure bar, 50 µm)  
 
Serial PMCA identification of PrP
CWD
 in an asymptomatic mouse:  
 Negative control mice and a single test mouse expiring with intercurrent disease 
at 161dpi, all of which were found negative for PrPCWD by WB and IHC, were further 
evaluated using sPMCA over three rounds of amplification.  In three repeated sPMCA 
experiments, a subclinical prion infection was confirmed in the remaining mouse 
inoculated with tissue from deer #134 (mouse #Tg 2-B).  None of the brains from mice 
inoculated with negative control tissues amplified PrPCWD, while positive control mice 




Figure 2.5. Serial PMCA detection of CWD prions in inoculated mice.  Brain from a 
single tg5037 mouse (mouse Tg 2-B) was WB and IHC negative yet amplified PrPCWD 
after three rounds of sPMCA (lane 2), as did a positive control mouse (lane 1).  Mice 
inoculated with tissues from sham-inoculated deer failed to amplify PrPCWD (lanes 3 and 
4).    
 
Analysis of individual neural and lymphoid tissues by sPMCA:  
 To further examine the terminal distribution of CWD prions following oral 
exposure to presumed low concentrations of infectious prions in excreta, we analyzed 
individual tissue samples from control and test deer using sPMCA.  Positive control 
tissues in these experiments included two deer inoculated PO with saliva from CWD+ 
deer (deer #113 and 122), while identical tissue sets were collected from negative control 
deer #103, 123, and 4488.  By analyzing obex and retropharyngeal tissues individually, 
PrPCWD amplification was found to occur exclusively in obex preparations from study 
animals.  The levels of amplification observed were compared to serial dilutions of 
positive control tissue, and correlated to an approximately 20-40 fold dilution of 1% 
homogenate of deer #106 obex in NBH (data not shown).  These results were surprising 
given that it has been reported that PrPCWD is commonly found to accumulate in the 
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retropharyngeal lymph node, and other lymph nodes of the alimentary tract, prior to its 
appearance in the obex in experimental oral (Sigurdson, Williams et al. 1999) and natural 
CWD infections (Keane, Barr et al. 2008; Keane, Barr et al. 2008).  We therefore sought 
to determine whether other lymphoid tissues were correspondingly bypassed in these 
deer. 
 
 In an attempt to understand if a strictly neural route of CNS invasion might have 
occurred, we performed sPMCA on the mesenteric, mediastinal, and ileocecocolic lymph 
nodes, tonsils, vagus nerve, intermediolateral spinal cord segments, and ileum from the 
above 5 urine/feces exposed deer and from positive and negative control deer. 
Surprisingly, while PrPCWD was amplified from a terminal tonsil biopsy of a single study 
deer, neither vagus nerve, nor the retropharyngeal, mesenteric, mediastinal or 
ileocecocolic lymph nodes were positive for PrPCWD by sPMCA in any of the deer orally 
exposed to urine and feces from CWD+ donors (Figure 2.6).  As might be expected, 
protease-resistant prion protein was amplified from both neural and lymphoid tissues 
from the positive control deer, while no amplification was observed in corresponding 
tissues from negative control deer or multiple unseeded NBH controls examined 


























































































































































































































































































































































































































































































































































































































































































































































































































































 The salient feature of chronic wasting disease is its facile transmission among 
captive and free-ranging cervids. Prior research has demonstrated infectious prions in the 
saliva and blood using cervid bioassay (Mathiason, Powers et al. 2006; Mathiason, Hays 
et al. 2009).  However, those experiments were unable to identify PrPCWD in the tissues of 
deer orally exposed to combined urine and feces, even though our later studies employing 
Tg[CerPrP] mouse bioassay demonstrated very low levels of prion infectivity (surmised 
by long incubation/survival periods) in the urine of some CWD+ deer (Haley, Seelig et 
al. 2009).  In the current study, the enhanced sensitivities of sPMCA and intracerebral 
inoculation of cervid PrP-tg5037 mice have led us to conclude that at 19 months post 
inoculation, low levels of amplifiable and infectious CWD prions were in fact present in 
the brains of the exposed, yet asymptomatic and conventional assay negative, deer from 
our original oral bioassay studies (Mathiason, Powers et al. 2006; Mathiason, Hays et al. 
2009), thereby inferring that low levels of prion infectivity were present in the urine/feces 
inocula.  Whether the apparent low concentrations of prions amplifiable from the obex of 
the urine/feces recipients could represent a persistent non-pathogenic prion carrier state, 
or rather (perhaps more likely) indicates that an observation period far exceeding 19 
months would be required to reveal ultimately pathogenic prion infections in these 
animals, remains undetermined.   
 
 Because the initial bioassay deer were inoculated with both urine and feces, our 
present findings cannot identify the specific excreta involved in CWD transmission.  It 
seems likely, however, that both excreta may play an important role in the horizontal 
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transmission of CWD, given the later demonstration of prion infectivity in urine (Haley, 
Seelig et al. 2009) and feces (Tamguney, Miller et al. 2009)  of CWD+ deer using 
transgenic mouse bioassay.  Further experiments, employing cervid bioassay of separated 
excreta and sPMCA are underway to better answer this question. 
 
 In the initial sPMCA and bioassay experiments, to maximize use of available 
tg5037 mice, we analyzed homogenates of combined neural (obex) and lymphoreticular 
(LRS) tissues for the CWD prion protein.  Information on the pathogenesis of CWD 
indicates that, following oral exposure, PrPCWD is first detectable in lymphatic tissues 
draining the alimentary tract, especially retropharyngeal lymph node and Peyer’s patches 
(Sigurdson, Williams et al. 1999; Sigurdson, Spraker et al. 2001; Fox, Jewell et al. 2006; 
Keane, Barr et al. 2008; Keane, Barr et al. 2008).  Thereafter, it is assumed that neural 
transport may be occur through anterograde ascension via myenteric or LRS sympathetic 
and parasympathetic neural networks to the central nervous system (Sigurdson, Spraker 
et al. 2001), paralleling the pathogenesis of sheep scrapie (Beekes and McBride 2007; 
van Keulen, Bossers et al. 2008).  Thus the earliest and most prominent CNS PrPCWD 
accumulation is in the dorsal motor nucleus of the vagus in the obex (Peters, Miller et al. 
2000; Spraker, Balachandran et al. 2004; Keane, Barr et al. 2008), followed by 
centrifugal neural spread to peripheral sites.  We were therefore surprised to find that 
PrPCWD amplification was restricted to the obex of 4 out of 5 urine/feces inoculated deer.  
As with any test, there is the potential for poor sample quality to affect test results; this 
may explain the absence of detectable PrPCWD in the lymphoid tissues of urine and feces 
inoculated deer.  However, based on the abundance of PrPCWD in lymphoid tissues of 
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saliva-inoculated deer, we are left with the interpretation that CWD prions may have 
bypassed amplification in the LRS of these deer.  While these results are in contrast to the 
current concept of CWD pathogenesis (Sigurdson, Williams et al. 1999; Sigurdson, 
Spraker et al. 2001; Mathiason, Powers et al. 2006; Keane, Barr et al. 2008), absence of 
LRS involvement has been observed in natural cases of scrapie (Jeffrey, Martin et al. 
2001; Jeffrey, Ryder et al. 2001; Jeffrey, Begara-McGorum et al. 2002; Siso, Jeffrey et al. 
2009) and bovine spongiform encephalopathy (BSE) of cattle and sheep (Terry, Marsh et 
al. 2003; Wells 2003; Beekes and McBride 2007; van Keulen, Bossers et al. 2008).  In 
scrapie-infected sheep, for example, the absence of scrapie amplification in the LRS as a 
result of host PrP genotype, limited dose exposure, tissue route/conduit, or prion strain 
selection are all supported by available evidence (Jeffrey, Martin et al. 2001; Jeffrey, 
Ryder et al. 2001; Jeffrey, Begara-McGorum et al. 2002; Siso, Jeffrey et al. 2009), and 
may also be plausible in cases of CWD.  The deer included in our study were of two PrP 
genotypes at position 96, expressing either G/G or G/S, both of which have been shown 
to be LRS competent in the pathogenesis of CWD, although slower pathogenesis has 
been linked to 96S (Wolfe, Spraker et al. 2007; Keane, Barr et al. 2008).  In naturally 
occurring cases of bovine spongiform encephalopathy, the BSE prion seems to 
exclusively utilize autonomic neural pathways for neuro-invasion, a defining 
characteristic of BSE (Terry, Marsh et al. 2003; Wells 2003; Beekes and McBride 2007; 
van Keulen, Bossers et al. 2008).  It is possible that CWD strains may eventually be 
uncovered with BSE-like phenotypes which could be selected for by low dose exposure.  
Nevertheless, there have been no reports of PrPCWD detection solely in the CNS of 
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infected deer.  Thus the exact route by which CWD prions accessed the CNS of deer in 
the present study remains unidentified. 
 
 Detection of CWD prions in the present study samples relied heavily on sPMCA, 
with cervid transgenic mouse bioassay as a confirmatory assay.  Given the risk of 
spurious positive results possible with multiple rounds of sPMCA, whether due to 
“spontaneous generation” or contamination (Deleault, Harris et al. 2007; Agrimi, 
Cosseddu et al. 2008; Barria, Mukherjee et al. 2009), we took great care to minimize this 
risk using approaches that parallel those to reduce cross-contamination in nested PCR.  
These precautions took two forms: avoiding cross-contamination during sample 
collection and initial processing, and prevention of intra-experimental cross-
contamination.  Animals were necropsied in order of approximate level of infection 
(based on inoculation material and known tonsil biopsy results), beginning with negative 
controls, followed by animals exposed yet biopsy negative throughout the study, and 
finally exposed, biopsy positive animals.  Fresh necropsy instruments were used for each 
necropsy, with the central nervous system tissues removed at the completion of the 
necropsy.  All study and control samples were then prepared in parallel using identical 
equipment and reagents.  Normal brain homogenate substrates were prepared and loaded 
in sPMCA plates in a laboratory not used for prion study using disposable or sterilized 
equipment.  Negative controls included multiple samples from both sham-inoculated 
cervids and uninfected Tg[CerPrP]-tg5037 mice.  In addition, the number of 
amplification rounds was limited to three to help ensure specificity.  Perhaps most 
importantly, the positive sPMCA results identified in brain and lymph node homogenates 
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were confirmed by bioassay to provide support the conclusion that the sPMCA+ tissues 
did in fact harbor infectious prions. 
 
 In summary, we provide evidence for the presence of infectious prions in the 
brains of conventional prion-assay-negative deer orally exposed 19 months earlier to 
urine and feces from CWD-infected donor deer.  This apparent low level of prion 
infection was amplified by sPMCA, confirmed by Tg[CerPrP] mouse bioassay, and 
detected only in the obex region of the brain.  These results demonstrate the potential for 
CWD prion transmission via urine and/or feces, and highlight the application of more 
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Detection of CWD Prions in Salivary and Urinary Tissues of Deer: Potential Mechanism 




















Saliva and urine are thought to play an important role in the transmission and 
pathogenesis of chronic wasting disease (CWD) in captive and free-ranging cervids.  We 
have previously identified PrPCWD in a variety of excreta using serial PMCA (sPMCA) 
and bioassay; however the source of infectious prions in urine and saliva has yet to be 
identified.  In the present study, we applied sPMCA to tissues associated with saliva and 
urine production and excretion in an effort to seek proximal sources of prion shedding.  
Oropharyngeal and urogenital tissues, along with blood and obex from CWD-exposed 
cervids (comprising over 300 individual samples) were analyzed blindly in duplicate and 
scored based on apparent CWD burden.  PrPCWD was detected by 3 rounds of sPMCA in 
tissues associated with saliva and urine production and excretion, notably salivary gland 
and urinary bladder; whereas blood samples from the same animals and concurrent 
negative controls (n= 116 of 117) remained negative.  Route of inoculation and CNS 
burden appeared to play an important role in terminal prion distribution, in that IV-
inoculated animals and those with increasing CNS levels of PrPCWD had higher and more 
widely distributed accumulation in excretory tissues.  PMCA identification of PrPCWD in 
oropharyngeal and urogenital tissues – in the absence of detection by conventional 
methods – may indicate the presence of protease-sensitive infectious prions in excretory 
tissues not revealed by assays employing PK digestion or other means to remove PrPC 
reactivity. Thus evaluation of peripheral tissues via sPMCA may allow additional insights 





Chronic wasting disease (CWD) is an efficiently transmitted prion disease of 
cervids (e.g. deer, elk, and moose), and is the only known prion disease affecting free-
ranging, non-domestic animals.  The origins of CWD are uncertain, but the disease has 
been present in wild cervid populations of northern Colorado and southern Wyoming for 
over 40 years (Williams and Young 1980; Williams and Young 1982).  Since its 
discovery, CWD has been identified in both captive and free-ranging cervids in 17 states, 
2 Canadian provinces, and Korea (Sigurdson 2008).  With intensified national 
surveillance efforts, CWD has been detected in areas previously thought to be free of 
infection, including recent discoveries in Virginia and Missouri (www.promedmail.org 
2010a; www.promedmail.org 2010b). The prevalence of CWD varies across North 
America, but can be as high as 30% in some areas of Colorado or in captive populations 
(Keane, Barr et al. 2008).   
While much remains to be learned about the mechanisms of horizontal CWD 
transmission, a number of recent studies have shed some light on the potential routes of 
CWD shedding and transmission in nature.  Initial experiments demonstrated 
conclusively that the environment and environmental fomites are capable of transmitting 
disease in both outdoor and later indoor cervid housing facilities (Miller, Williams et al. 
2004; Mathiason, Hays et al. 2009).  Subsequently, both saliva and blood were shown to 
efficiently transmit infection from CWD+ animals to naïve white-tailed deer (Mathiason, 
Powers et al. 2006).  The role of urine and feces was less clear following these early 
experiments; however the use of transgenic mouse bioassay in the evaluation of excreta 
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from infected individuals, in addition to more sensitive evaluation of subclinically 
infected deer inoculated with urine and feces via PMCA, later demonstrated true 
infectious potential in both forms of excreta (Haley, Mathiason et al. 2009; Haley, Seelig 
et al. 2009).    
The identification of infectious prions in bodily fluids represents an important 
step in understanding both the pathogenesis and transmission of CWD; however the 
proximal source of the agent in these excreta has not been examined in depth.  A variety 
of organs and tissues are responsible for producing and excreting both saliva and urine.  
In cervids, saliva is an aqueous solution composed of a variety of proteins and 
electrolytes produced primarily by sublingual, submaxillary, and parotid salivary glands 
(Kay 1960; Fickel, Goritz et al. 1998).  During the course of rumination, gastric fluids 
have also been shown to intermix with saliva produced in the upper gastrointestinal tract 
of ruminants (Beauchemin 1991).  When evaluated cytologically, a number of different 
cell types may be found in this protein-laden fluid, including epithelial cells, 
lymphocytes, and neutrophils derived from the tongue, oral mucosa and associated 
lymphatic tissues (Kutta, May et al. 2006).  Urine, on the other hand, is produced through 
active filtration of circulating blood by the kidneys, removing the majority of proteins in 
favor of excretion of metabolic waste, electrolytes, and small amounts of water (Maloiy 
and Scott 1969; Hove and Jacobsen 1975).  Prior to being excreted, urine passes through 
the ureters to the urinary bladder and into the environment via the ureter; transitional 
epithelial cells and lymphocytes from each of these tissues are a common finding in 
cervid urine.  Thus, there are many potential sites for the excretion of CWD prions into 
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both saliva and urine, and identification of all likely sources will assist our understanding 
of both pathogenesis and transmission in the natural host. 
Although there has been anecdotal evidence of immunohistochemical (IHC) 
identification of prions directly in excretory organs and tissues, for example in the 
kidneys of scrapie-affected sheep (Siso, Jeffrey et al. 2008) and in ectopic lymphoid 
aggregates in CWD+ deer (Hamir, Kunkle et al. 2006), as well as lingual tissues of 
hamsters inoculated with the HY strain of transmissible mink encephalopathy (Mulcahy, 
Bartz et al. 2004; DeJoia, Moreaux et al. 2006), the ability to reliably identify protease-
resistant forms of the prion protein in cervid excretory tissues using conventional IHC 
has proven difficult (Kitamoto, Mohri et al. 1989; Spraker, Miller et al. 1997; Foster, 
Parnham et al. 2001; Fox, Jewell et al. 2006; Balachandran, Harrington et al. 2010).  
Studies identifying genuine infectivity in excretory tissues is more limited, however, with 
reports of infectivity in parotid salivary gland of scrapie infected goats (Hadlow, Eklund 
et al. 1974) and kidneys of scrapie infected mice (Eklund, Kennedy et al. 1967).  In these 
particular studies, which have yet to be replicated as broadly in other model systems, a 
variety of urinary and oropharyngeal tissues were unfortunately overlooked, leaving out 
crucial data on tissue infection during the course of prion pathogenesis.   
Serial protein-misfolding cyclic amplification (sPMCA) is an assay that has 
proven utility in the detection of low levels of protease resistant, and potentially protease-
sensitive, forms of the infectious prion protein, without the need for lengthy and 
expensive mouse bioassay experiments (Saborio, Permanne et al. 2001; Soto, Anderes et 
al. 2005; Kurt, Perrott et al. 2007; Haley, Mathiason et al. 2009; Haley, Seelig et al. 
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2009).  In this study, we utilized a standardized sPMCA assay to detect PrPCWD in various 
tissues associated with salivary and urinary excretion (e.g. salivary glands, tongue, 
kidney, ureter, and urinary bladder) from 28 experimentally challenged white-tailed deer, 

















MATERIALS and METHODS 
Infected cervids:  
 Twenty-eight white-tailed deer (Odocoileus virginianus) were exposed to CWD 
from positive and negative sources in various forms (e.g. urine and feces, saliva, 
environmental fomites, blood, or brain tissue) and by various routes (e.g. orally, 
intravenously, intraperitoneally, intracranially, or through environmental exposure).  Deer 
had been housed for previous transmission studies (Mathiason, Powers et al. 2006; 
Mathiason, Hays et al. 2009; Mathiason, Hayes-Klug et al. 2010; Mathiason, Hayes-Klug 
et al. (Under Review)), and all animals were inoculated and maintained in accord with 
Colorado State University IACUC guidelines.  The sources of inoculum included 
terminally-ill mule deer (Odocoileus hemionus) of unknown PrP genotype (courtesy of 
Michael Miller, Colorado Division of Wildlife), or compatriot white-tailed deer utilized 
in previous and concurrent studies of either of two genotypes: homozygous for glycine 
(i.e. G/G) at cervid PrP position 96, or heterozygous at that position, with alleles for both 
glycine and serine (G/S).  The deer were monitored for 16 – 27 months post inoculation 
(mpi), during which time the majority became tonsil-biopsy positive for CWD by 
immunohistochemistry (IHC).  Duration of clinical disease prior to necropsy ranged from 
0 (i.e. no clinical signs) to 72 weeks.  At scheduled necropsy dates, or when exhibiting 
signs of terminal disease, deer were euthanized and subjected to an extensive necropsy 
using fresh instruments and collection vessels for each individual, at which time bodily 
fluids and an array of tissues were collected and frozen at -80°C.  Animals that were not 
tonsil-biopsy positive for CWD prior to euthanasia were thoroughly evaluated for CWD 
infection after necropsy, which included IHC and western blotting (WB) of neural and 
84 
 
lymphoid tissues which have been shown to be early diagnostic sites for CWD (e.g. obex, 
retropharyngeal lymph nodes, and tonsils).  A complete description of animals, 
inoculation routes and sources, CWD status, time of first tonsil biopsy positivity in 
months-post-inoculation (mpi), incubation period at necropsy (in mpi), and duration of 










































































































































































Study samples and preparation:  
 Obex, parotid salivary gland, tongue, kidney, ureter, urinary bladder, and blood 
were collected at necropsy and frozen at -80°C.  Tissue samples were thawed briefly and 
10 – 50mg of each were trimmed individually and homogenized as a 1% solution (w/v) in 
PMCA buffer (1% triton-X 100 [v/v], 5mM EDTA, and 150mM NaCl in PBS adjusted to 
a pH of 7.2) using a FastPrep™ tissue homogenizer for 60s at power setting 6.5.  Whole 
blood samples remained suspended in 5% EDTA until sPMCA evaluation.  All tissues 
were prepared in individual microcentrifuge tubes and homogenized in parallel in the 
same machine concurrent with both positive and negative controls.  Sample preparation 
tubes were coded to allow for blinded evaluation by serial PMCA.    
 
Preparation of normal brain homogenate for sPMCA: 
 Normal brain homogenate (NBH), the substrate for prion conversion in vitro, was 
prepared from tg5037 mice in a room that had not previously been used for prion 
research.  Following euthanasia and perfusion with 5mM EDTA in phosphate-buffered 
saline (PBS), whole brain was collected from naïve tg5037 mice and placed on ice.  Brain 
homogenates were prepared as a 10% (w/v) solution in PMCA buffer with the addition of 
Complete Protease Inhibitors (Roche Pharmaceuticals, Indianapolis, IN) using a dounce 
homogenizer.  Homogenates were then centrifuged for 1 minute at 2000rpm and the 
supernatant frozen in single-experiment aliquots at –80ºC in a “prion-free” room until use 
in sPMCA.  Each preparation was composed of brain from 4-6 mice to minimize the 
influence of the expression variation of CerPrP or other co-factors (Browning, Mason et 
al. 2004; Angers, Seward et al. 2009).     
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Serial PMCA of tissues: 
 Tissue homogenates from CWD-exposed deer were blindly assayed, in duplicate, 
for PrPCWD by sPMCA.  All test samples were prepared in parallel with tissue-matched 
positive and negative controls as a 1% homogenate in PMCA buffer as described above 
and subsequently spiked into normal brain homogenate for amplification as described 
previously (Kurt, Perrott et al. 2007; Haley, Mathiason et al. 2009; Haley, Seelig et al. 
2009; Kurt, Telling et al. 2009).  Ten µl of test or control tissue homogenate were added 
to 50µl of NBH and assayed, in parallel and in adjacent wells of a 96-well plate (USA 
Scientific, Ocala, FL); along with normal brain homogenate prepared from unexposed 
tg5037 mice as additional, unseeded negative controls.  Plates were then sonicated using 
an ultrasonic processor (Misonix, Farmingdale, NY) and incubated at 37ºC.  Sonication 
parameters were set at 40s bursts at power level 7.0, followed by 30 minutes of 
incubation.  Ninety two cycles of sonication were performed over 48 hours, with a 10µl 
aliquot transferred to 50µl of fresh NBH for serial amplification.  Following each round 
of amplification, samples were evaluated by western blotting, as described below, for the 
presence of PrPCWD.  Each sample was given a score based on the number of rounds that 
particular sample was positive (a maximum of three in a three-round experiment), and the 
scores for each duplicate run were totaled to arrive at a final score, with “0” being the 
lowest and “6” being the highest score a given sample could receive.  In each 
experimental run, between 25 – 50% of samples evaluated were tissue-matched negative 
controls.  Additionally, 10 – 20% of the samples in a run were unspiked, normal brain 
homogenate negative controls.  Over the course of sPMCA experiments, multiple NBH 
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preparations were used, with each preparation consisting of between 4 - 6 source 
transgenic mouse brains to minimize individual differences in [CerPrP] expression levels.  
 
Serial PMCA of blood: 
 EDTA-preserved whole blood samples from CWD-exposed deer were blindly 
analyzed in duplicate as described above for tissues, with some modifications.  Using the 
protocol initially described by Tattum et al (Tattum, Jones et al. 2010), we spiked 1µl of 
whole blood into 100µl of normal brain homogenate.  Sixty µl of this preparation was 
added to a 96-well plate and analyzed by sPMCA.  Sonication parameters were set at 20s 
bursts at power level 7.5, followed by 30 minutes of incubation at 37°C.  One hundred 
forty-four cycles of sonication were performed over 72 hours, with a 10µl aliquot 
transferred to 50µl of fresh NBH for serial amplification.  Each sample was WB-
evaluated as described below for PrPCWD signal following each round of amplification.   
 
Serial PMCA of obex dilution series and approximation of tissue scores: 
 Preliminary dilution series of obex tissue from seven animals, deer #110, 111, 
113, 134, 137, 144, and 4119, collected and processed as described above, were made by 
diluting each of the initial 1% obex homogenates into 10% normal Tg[CerPrP] brain 
homogenate (NBH) at 1:10 dilutions ranging from 100 to 10-14 (i.e. overall dilutions of 
10-2 - 10-16).  Prior to diluting, the initial 1% obex homogenates were sonicated for 20s at 
power setting 7.0 in an ultrasonic processor.  Ten µl of each dilution was added to 50µl 
NBH and analyzed for three rounds of PMCA as described for tissues above.  Each 
dilution then received a score following western blotting; these scores were then used to 
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estimate the relative log obex dilution equivalent (LODE) scores of individual tissues 
within animals.  Correlation coefficients between obex dilutions and sPMCA scores were 
determined using a commercially available statistical software package (Microsoft Xcel 
2007). 
 
Western blotting (WB): 
 Following each round of sPMCA amplification, an aliquot of each sample was 
subjected to western blotting for evaluation of PrPCWD signal.  Fifteen µl of sample 
homogenate were mixed with 7µl of sample buffer (0.1% [v/v] triton-X 100 and 4%(w/v) 
SDS in PBS) and digested with 3µl proteinase-K at 500µg/ml (final concentration: 
60µg/ml) for 20’ at 37ºC followed by 10’  at 45ºC.  Eight µl of 4X running buffer were 
then added to the sample, followed by denaturation for 5’ at 95ºC.  Fifteen µl of this 
preparation were run on a pre-cast 12% SDS-PAGE gel (Invitrogen) in a Bio-Rad 
electrophoresis apparatus for 1 hour at 160mV.  Samples were then transferred to a 
PVDF membrane (Millipore) for 1 hour at 115mV in a Bio-Rad transfer apparatus.  
PVDF membranes were subsequently probed with a PrP-specific monoclonal antibody 
(BAR224-HRP) diluted 1:20,000 in 5% (w/v) powdered milk in 0.2% Tween-20 in tris-
buffered saline (TBST) for 1 hour.  Following washing with TBST, immunoreactivity 
was detected using an enhanced chemiluminescent detection system (ECL-plus, 






Evaluation of intra-run variability in duplicate experiments: 
 As all samples were run in duplicate, often on two different sonicating machines, 
we attempted to compare the intra-run variability in experimental results.  A 
commercially-available calculator for categorical Cohen’s kappa value was used to define 
the agreement of results between the two different experiments (Faculty.Vassar.edu 
2009).  As scores progressed linearly in the sPMCA evaluation, a linear weighted 
approach was used to calculate Cohen’s kappa.  Significance of correlation was 



















 In an effort to determine the proximal source of prions in saliva and urine, and to 
add crucial elements to our understanding of CWD pathogenesis, we blindly evaluated, in 
duplicate, a range of organs and tissues associated with saliva and urine production and 
excretion for PrPCWD amplification using a standardized sPMCA assay.  These tissues 
were then scored based on number of rounds demonstrating amplification; individual 
tissue scores were then grouped according to source of inoculum and correlated with 
intra-animal obex dilution scores.  
      
Detection of PrP
CWD
 in peripheral tissues of exposed deer by serial PMCA: 
   Using a serial PMCA protocol shown to amplify PrPCWD from both central and 
peripheral tissues in previous experiments, we blindly evaluated an array of tissues, from 
CWD-exposed and naïve deer, associated with salivary and urinary production and 
excretion, including salivary glands, tongue, kidney, ureter, and urinary bladder for 
evidence of PrPCWD accumulation.  In total, over 300 individual samples were evaluated, 
including 117 negative control samples.  Animals were initially grouped based on 
inoculum source (e.g. saliva, blood, urine and feces); specific tissue scores in each of 
these groups were averaged to determine mean tissue score for each group.  Next, 
animals were grouped according to obex score, and associated tissue scores were then 
averaged to determine the mean tissue score for each corresponding obex score.  In 
exposed animals, PrPCWD was amplified to varying degrees in all tissues evaluated (Table 
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3.2); with amplification patterns dependent on source of inoculation (Figure 3.1) and 
apparent obex burden (Table 3.3).  Animals inoculated IV or IP with whole blood 
demonstrated the most widespread distribution of amplified PrPCWD, while PO 
inoculation of either saliva or urine and feces revealed a more limited distribution.  
Interestingly, the amplification in some peripheral tissues, such as salivary gland and 
urinary bladder, rivaled or eclipsed amplification observed in the obex (e.g. salivary 
gland and urinary bladder from deer 144, urinary bladder from deer 4461, etc.).  Among 
117 negative control samples, a single false positive was identified in a kidney section 
from deer #103.  This particular sample was evaluated in four separate experiments, and 
received a total score of “1” in a single sPMCA experiment; no amplification was 














Table 3.2: Summary of sPMCA results in blood and tissues associated with production 
and excretion of saliva and urine in CWD-exposed deer.  Scores varied among routes of 
inoculation and inoculation sources.  Occasionally, peripheral tissues rivaled or exceeded 
those of the obex (i.e. deer #144 salivary gland and urinary bladder, tongue and ureter of 
deer #4461) 
NA: sample not available.  




Figure 3.1: Radar plot summaries of tissue sPMCA results. Animals were grouped 
according to source of inoculum (blood, saliva, etc) and route of inoculation.  Central 
concentric rings represent a score of “1,” with scores progressing radially outward up to a 
score of “6.”  For each source of inoculum, colored wedges represent the mean individual 
score for that particular tissue.  Patterns of distribution varied with both source and route 
of inoculum, with the most widely distributed patterns identified in animals inoculated 
with blood either IV or IP.  Animals inoculated orally with either saliva or urine and 
feces had a much more limited tissue distribution, while tissues affected in animals 
inoculated IC with CWD+ brain were limited almost exclusively to salivary glands and 




Table 3.3: Correlation of intra-animal obex scores with those of individual blood and 
tissue scores.  Data represents average tissue scores within obex score categories.  As 
obex score increases from “1” to “6,” individual tissues show a corresponding trend of 
increase in most cases. 
† In the course of sPMCA evaluation, no animals were identified with an obex score of 
“5.” 
  
Three-rounds of serial PMCA are not sufficient for PrP
CWD
 amplification in cervid whole 
blood: 
 Serial PMCA has been shown to be effective in the amplification of blood-borne 
PrPres in various models of prion disease, including scrapie in both the natural host and 
mouse models.  To date, however, no protocol has proven effective for amplifying PrPres 
in the CWD model system – despite adequate evidence that blood and its components 
harbor infectious amounts of CWD prions (Mathiason, Powers et al. 2006; Mathiason, 
Hayes-Klug et al. 2010).  Various sPMCA protocols have been described for blood 
evaluation (e.g. Castilla, Saa et al. 2005; Murayama, Yoshioka et al. 2007); however we 
chose a protocol that has recently been shown effective in a model of naturally-acquired 
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scrapie in sheep (Tattum, Jones et al. 2010).  In an effort to demonstrate the feasibility of 
amplifying PrPCWD in cervid whole blood, or alternatively to rule out blood 
contamination in tissue evaluations, we blindly examined twenty-eight whole blood 
samples from both CWD-exposed and naïve deer.  In three rounds of sPMCA, all 
samples remained negative for PrPCWD amplification (Table 3.2 and 3.3, Figure 3.1), 
ruling out blood contamination of tissues in a limited number of PMCA rounds, though 
perhaps not ruling out the feasibility of sPMCA to detect PrPCWD in further rounds of 
PMCA. 
 
Preliminary evaluation of obex dilutions to estimate tissue log obex dilution equivalent 
(LODE) scores:     
 Seven deer with variable levels of amplifiable PrPCWD in both obex and peripheral 
tissues (deer #110, 111, 113, 134, 137, 144, and 4119) were selected for sPMCA 
evaluation of 10-fold obex dilutions.  Dilutions of 1% obex homogenates ranging from 
100 – 10-14 (i.e. overall dilutions of 10-2 – 10-16) were evaluated in the standardized three-
round PMCA assay, and each dilution was assigned a score as described for tissues above 
(Figure 3.2a [orally inoculated deer] and 3.2b [IV inoculated deer]).  Individual 
peripheral tissues were then conservatively correlated with the lowest obex dilution 
receiving that particular score and assigned a log obex dilution equivalent (LODE) score.  
In the limited number of deer evaluated, tissue LODE scores were greatest in salivary 
gland and urinary bladder, which scored as high as 10-1 to 10-3, respectively (Table 3.4).  
Trend lines were generated from the data by a mathematical software program (Microsoft 
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Xcel).    Coefficients of correlation between these trend lines and the corresponding data 















































































































































































































Table 3.4: Tissue LODE scores of individual oropharyngeal and urogenital tissues.  
Values conservatively represent the log10-fold dilution of obex required to achieve a score 
equivalent to that particular tissues score.  Salivary gland and urinary bladder generally 
exhibited the greatest scores, approaching 10-1 to 10-4 obex dilution equivalents, 
respectively.  
 
Individual intra-run sPMCA scores show a high level of agreement: 
 Using a commercially-available calculator for categorical Cohen’s kappa, the sum 
of results available from blood and tissue sPMCA experiments were analyzed to 
determine the level of agreement between duplicate runs.  A summary of the categories 
and scores achieved in duplicate runs on sonicators “A” and “B” are presented in Table 
3.5.  Because the progression of scores for each experiment is a linear one (i.e. from “0” 
– “3”), the kappa value was weighted linearly.  The observed kappa value for the sum of 
sPMCA experiments was 0.80 (SE: 0.031; 95% CI: 0.74 – 0.87), which is considered as 
substantial to near-perfect agreement under guidelines proposed by Landis and Koch 




Table 3.5: Summary of scores achieved in duplicate sPMCA experiments.  Tissues were 
evaluated in duplicate on two different sonicators – “A” and “B,” receiving a score 
ranging from 0-3 in each replicate.  Corresponding scores from duplicated experiments 
were tallied and evaluated categorically to derive a value for Cohen’s kappa (0.80+/-














 Among the many described transmissible spongiform encephalopathies (TSE’s) 
of animals and man, chronic wasting disease is unique in its relatively high levels of 
transmissibility.  Using serial PMCA and transgenic mouse bioassay, we have previously 
demonstrated infectious prions in both urine and saliva, as well as in deer that remained 
conventional-test negative long after oral exposure to urine and feces (Haley, Mathiason 
et al. 2009; Haley, Seelig et al. 2009).  While these studies demonstrate the important role 
of bodily fluids in horizontal spread of CWD, the source of infectious prions and the 
kinetics of shedding in excreta remain unknown.     
 In a number of historical, cross-sectional studies in CWD-endemic cervid herds, 
conventional immunohistochemistry and western blotting failed to demonstrate protease-
resistant prions in any of the organs of production and excretion of either saliva or urine 
(Spraker, Miller et al. 1997; Fox, Jewell et al. 2006; Balachandran, Harrington et al. 
2010).  Only recently has the potential for a protease-sensitive, yet still infectious, form 
of the prion protein – denoted sPrPSc – been identified (Colby, Wain et al.; Safar, Wille et 
al. 1998; Safar, Geschwind et al. 2005; Thackray, Hopkins et al. 2007; Jansen, Head et al. 
2010); because of the necessity for harsh proteolytic or formic acid treatments, 
conventional assays used to screen peripheral tissues may be handicapped in their ability 
to detect this form of PrP.  Anecdotally, however, protease-resistant prions have been 
identified in ectopic lymphoid aggregates in the kidneys of CWD-exposed deer, but no 
conclusions could be drawn the infectivity of this particular sample and on the likelihood 
this phenomenon may play a role in prionuria in nature (Hamir, Kunkle et al. 2006).  
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Previous studies in hamsters have also linked nephritis with concurrent prionuria (Kariv-
Inbal, Ben-Hur et al. 2006), a condition demonstrated in those deer whose urine was 
pooled in my initial bioassay studies (Haley, Seelig et al. 2009).  Using IHC, protease-
resistant prion has also been demonstrated in a variety of lingual tissues, including lingual 
epithelium, in hamsters inoculated with the hyper (HY) strain of transmissible mink 
encephalopathy (DeJoia, Moreaux et al. 2006), while early mouse bioassay experiments 
have also identified infectious prions in the salivary glands of scrapie-exposed goats 
(Hadlow, Eklund et al. 1974).  Each of these studies, whether examining oral or 
urogenital tissues, again raises questions regarding the ultimate mechanisms involved in 
prionsialia and prionuria – specifically: (1) from where do infectious prions arise in these 
bodily fluids; (2) are infectious prions transmitted in a cell-free or cell-associated form; 
and (3) do infectious prions transmitted in excreta occur in their traditional, protease-
resistant form, or a more elusive protease-sensitive species? 
 Based on our previous studies incorporating sPMCA to amplify very low levels of 
PrPCWD in nervous and lymphoid tissues of exposed deer (Haley, Mathiason et al. 2009), 
we attempted to further evaluate a number of organs and tissues associated with saliva 
and urine production and excretion, including salivary gland, tongue, kidney, ureter, and 
urinary bladder.  As sPMCA has also been shown capable of amplifying both protease-
resistant and -sensitive forms of PrPSc (Pastrana, Sajnani et al. 2006), the absence of 
protease-resistant forms in these tissues would not preclude positive amplification.  After 
blind evaluation by sPMCA, in duplicate, we were able to identify PrPCWD in each of 
these tissues to varying degrees, with experimental results showing high levels of 
agreement between runs.  Tissue variation was related to both the source and route of 
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inoculate an animal was exposed to (e.g. IV whole blood, PO urine and feces, etc), as 
well as the apparent PrPCWD burden within the obex of the individual animal.  Tissue 
distribution variation with route of inoculation has been described in both viral and 
bacterial infections (Singh, Singh et al. 1987; Bravata, Holty et al. 2007; Prentice and 
Rahalison 2007; Maisner, Neufeld et al. 2009), so this finding is perhaps not surprising.  
Likewise, in the case of neurotropic viruses, peripheral tissue levels of virus often 
positively correlate with central nervous system burden (Charlton, Casey et al. 1983).  A 
detailed evaluation of the tissue distribution of PrPCWD in naturally-occurring cases may 
reveal patterns corresponding with those described in this study, which may help identify 
prevailing routes of transmission occurring in nature.  Additionally, these findings point 
to an increased risk of bodily fluid transmission with the progression of clinical disease.      
 What the findings of this study do not reveal is the sequential appearance of 
amplifiable prions in peripheral tissues.  It has often been argued that TSE’s follow a 
pattern of centripetal spread from the periphery to the central nervous system (via either 
the peripheral nervous system or the lymphoreticular systems), followed by centrifugal 
spread back to peripheral organs (Glatzel and Aguzzi 2000; Dormont 2002; Bartz, Dejoia 
et al. 2005; Unterberger, Voigtlander et al. 2005; Beekes and McBride 2007; van Keulen, 
Bossers et al. 2008).  The results of this study argue that peripheral infection may occur 
concurrently with central invasion – given that peripheral levels often rival or exceed 
those of the obex, long considered a “gold standard” tissue for the definitive 
identification prion infection of deer and other ruminants (Wells, Hancock et al. 1989; 
Ersdal, Ulvund et al. 2003; Joly, Samuel et al. 2006; Keane, Barr et al. 2008).  The 
amplification ability of PrPCWD, either in vivo or in vitro, may explain some of the scoring 
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variation between tissues, though compared to obex, the relative distributions would be 
expected to be more consistent.  We therefore evaluated log obex dilution equivalent 
(LODE) scoring of peripheral tissues, which conservatively demonstrated that, in most 
cases, excretory tissues, notably salivary gland and urinary bladder, score several log-fold 
dilutions lower than those observed in undiluted obex.  To further understand the 
centripetal and centrifugal dissemination of CWD prions, the present findings warrant a 
sequential evaluation of the peripheral prion distribution of via sPMCA – both within 
excretory tissues as well as nervous and lymphoreticular conduits – of serially-exposed 
animals. 
 In summary, this study demonstrates for the first time amplifiable PrPCWD in 
various organs and tissues associated with prionsialia and prionuria.  The ultimate source 
and mechanism of release into bodily fluids remain unknown, though elevated levels in 
both salivary gland and urinary bladder provides strong evidence that these tissues play a 
crucial role in prion excretion.  In addition, the source and route of inoculation weighed 
heavily on the terminal peripheral distribution of PrPCWD, as did an individual’s apparent 
central nervous system burden.  Finally, while this discovery provides evidence for prion 
invasion of peripheral excretory tissues, the timing of infiltration during CWD infection 
and the protease resistance profile of these prions warrant future studies in serial 
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CONCLUSIONS AND FURTHER DIRECTIONS 
 
Through the investigation of terminal bodily fluid samples and tissues of CWD-
exposed white-tailed deer, I have shown that:  (1) both saliva and urine harbor infectious 
CWD prions, as demonstrated in Tg[CerPrP] bioassay and serial PMCA, (2) serial 
PMCA is sufficiently sensitive in detecting PrPCWD in conventional test-negative tissues, 
and these tissues also harbor true infectivity through the transfer of infection in the 
Tg[CerPrP] bioassay system, and (3) serial PMCA is capable of detecting PrPCWD in 
tissues involved in the production and excretion of saliva and urine, notably salivary 
gland and urinary bladder, and the levels of PrPCWD in these organs correlate both with 
source and route of inoculum as well as central nervous system burden.     
Although I have obtained preliminary data on the relative peripheral tissue levels 
of PrPCWD, a full evaluation of the obex of deer used in this particular study is necessary.  
I also plan to evaluate other tissues potentially involved in fecal shedding by sPMCA, 
including elements of the gastrointestinal tract.  The information gained through 
continued investigations of these tissues will provide further information on the 
pathogenesis of CWD and the dynamics of peripheral infection.  Even at our present level 
of understanding, though, the data raises significant questions surrounding the role of 
peripheral tissues in either centrifugal or centripetal dissemination of CWD prions to or 
from the central nervous system, which mandate study of the kinetics of peripheral 
infection in naturally exposed deer.  Serial necropsies of infected deer, followed by a 
thorough evaluation of peripheral tissues via sPMCA (including organs involved in 
production and excretion of urine, feces, and saliva, as well as neural and lymphoid 
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tissues) would allow a “moving picture” analysis of the pathogenesis of CWD, as 
opposed to the static images of pathogenesis we now have for prion diseases. 
While I feel confident that I have generated significant information on the relative 
levels of PrPCWD in both central and peripheral tissues using both a crude, semi-
quantitative sPMCA scoring system and an approach utilizing log-obex dilution 
equivalent scores, there is very little information on the relationship between the apparent 
amplification ability of a given tissue and its actual infectivity, i.e. how does the 
amplification level of a tissue correlate with its infectivity?  In the second chapter, I 
evaluated tissues both by sPMCA and Tg[CerPrP] bioassay; to my knowledge this is the 
only manuscript that at least superficially addresses a correlation between amplification 
and infectivity in either unknown or conventional test-negative samples.  To further 
evaluate the relationship between sPMCA amplification and infectivity, a large-scale 
evaluation of CWD in endemic areas is warranted.  To that end, I have begun blindly 
evaluating a small subset of Rocky Mountain elk (Cervus elaphus) from Rocky Mountain 
National Park, where the prevalence of CWD approaches 11% in this species (Jenny 
Powers, personal communication).  Archived tissue samples from this subset of animals 
include obex, recto-anal mucosa associated lymphatic tissue (RAMALT), tonsil, and 
retropharyngeal lymph nodes, and each of these has previously been evaluated for 
PrPCWD by IHC.  By evaluating individual tissues blindly by sPMCA and determining 
their respective scores, a data base of sPMCA and IHC results from a naturally exposed 
population may be obtained.  This information can then be used in the design of 
transgenic mouse bioassay experiments, from which incubation periods can then be 
correlated to both IHC and sPMCA results.  Bioassay, the gold standard for prion 
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presence in a particular sample, would also prove useful in the direct comparison of the 
sensitivity and specificity of both IHC and sPMCA, and could additionally assist in 
defining the true prevalence of CWD in the Rocky Mountain National Park elk herd.          
While the identification of CWD prions in peripheral tissues is an exciting 
discovery that may lead to future understanding of CWD and prion disease pathogenesis 
and transmission, the “Holy Grail” of prion amplification assays is to be the first to apply 
it in the early identification of TSE infection in clinically relevant samples, specifically 
urine, saliva, or blood samples.  In the first chapter, I demonstrated sPMCA amplification 
of PrPCWD in a concentrated urine sample from a pooled set of animals; this report is still 
a long way from unearthing that Holy Grail.  The repeated, blinded amplification of 
PrPCWD in biological fluids has proven elusive over the course of the research presented 
in this dissertation, despite the apparent ease of amplification in tissues.  Perhaps this is 
related to either the conformation or cellular environment present in tissues.  I believe 
successful prion amplification in bodily fluids will first require development of the 
sPMCA assay for use in either cell culture or yeast models, where the sPMCA milieu 
may be specifically altered and optimized for cellular suspensions.  Until then, I am 
fortunate to have a wealth of bodily fluid samples from the National Park Service, in 
addition to those tissue samples described above, with which to continue optimization of 
sPMCA in excreta.  
Based on the studies presented in this thesis, it is my firm belief that sPMCA has 
a sensitivity far exceeding that of conventional IHC and western blotting.  It seems 
plausible that the enhanced sensitivity is related to the apparent ability of sPMCA to 
amplify a protease-sensitive form of PrPres, denoted “sPrPres.”  This isoform of the 
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infectious prion protein was first identified through the use of the conformation-
dependent immunoassay (CDI), which takes advantage of variable epitope exposure in 
the infectious prion protein and avoids the need for protease digestion.   Because 
traditional, in vitro prion detection methods rely on harsh proteolytic treatment steps to 
discriminate PrPres from the normal cellular isoform, it is likely that sPrPres, if truly 
present in vivo, goes unnoticed in subclinical animals, their peripheral tissues and bodily 
fluids.  What is certain is that a complete understanding of the role of sPrPres in 
pathogenesis and transmission is necessary if we ever hope to control the unchecked 
spread of naturally occurring prion diseases. 
Finally, the research presented in this thesis, and the future avenues I hope to 
explore, will provide us with crucial information on the pathogenesis of CWD that, like 
scrapie in sheep, has the incredible ability to spread efficiently between susceptible 
members of the host species.  As mentioned previously, though, CWD and scrapie seem 
to be unique in this aspect among the prion diseases, while prion diseases factoring more 
prominently in the public eye, like Creutzfeldt-Jakob disease (CJD) and bovine 
spongiform encephalopathy (BSE), seem to only rarely transmit horizontally – usually 
only as a result of human intervention (e.g. blood transfusions or the feeding of ruminant 
meat and bone meal).  Parallel studies of the pathogenesis and peripheral dissemination 
of natural cases of CJD and BSE are warranted to uncover why it is that these agents lack 
efficient mechanisms of transmission, shedding further light on how CWD and scrapie 
accomplish this feat.   
 The studies comprising this thesis have contributed to furthering the 
understanding of the transmission and pathogenesis of chronic wasting disease.  
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Moreover, these studies lay an important foundation for future CWD studies, which will 
answer questions that enhance our understanding of the various forms of the prion protein 
in all species affected.   
 
 
 
